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ABSTRACT 
Low circulating vitamin D levels have been linked to increased risks of cancer by 
epidemiologic studies, and preclinical research has demonstrated clear antitumor activities of 
vitamin D against various types of cancers. Calcitriol (1α, 25(OH)2 D3), the active form of 
vitamin D,  has been shown to inhibit proliferation, induce differentiation, and activate apoptosis 
in colon cancer cells. However, the mechanism of calcitriol’s antitumor action remains poorly 
defined and the hypercalcemic side effect of vitamin D limits its use as an anti-cancer agent. To 
understand its mechanism of action in tumor suppression, we investigated the effects of calcitriol 
on microRNA expression in colon cancer cells. We identified miR-627 as the microRNA whose 
expression was most significantly stimulated by calcitriol. Furthermore, JMJD1A (jumonji 
domain containing 1A), the gene encoding a histone demethylase, was identified as the target of 
miR-627.  It has been reported that JMJD1A is upregulated in colon cancer during hypoxia. 
Increased JMJD1A expression decreases the histone methylation on the promoters of target 
genes such as adrenomedullin (ADM) and the growth and differentiation factor 15 (GDF15) and 
increases their expression, which promotes tumor growth. By downregulating JMJD1A, miR-
627 mediated the effects of calcitriol to increase histone H3K9 methylation and to suppress the 
expression of growth-promoting genes, such as GDF15. Calcitriol also induced miR-627 and 
downregulated JMJD1A in colon cancer xenografts in nude mice. Calcitriol significantly 
suppressed the growth of colon tumors in nude mice, whereas colon tumor xenografts with stable 
JMJD1A-UTR expression showed resistance to the Calcitriol treatment, confirming the critical 
role of miR-627 in Calcitriol induced tumor suppression. Overexpression of miR-627 decreased 
JMJD1A and suppressed colon cancer growth both in vitro and in vivo. In addition, we found 
that miR-627 expression was decreased in human colon adenocarcinomas compared with 
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controls. These results suggest that, miR-627 is a major epigenetic regulator in vitamin D 
induced growth inhibition. MiR-627 and JMJD1A may serve as potential targets to exploit the 
antitumor activity of vitamin D without eliciting its hypercalcemic side effect. 
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CHAPTER 1: BACKGROUND INFORMATION; OBJECTIVES AND SPECIFIC AIMS; 
MATERIALS AND METHODS 
 
1.1. Background information  
1.1.1. Colorectal cancer 
Colorectal cancer develops in the colon or the rectum and it progresses very slowly over 
a period of 10 to 15 years (Kelloff G.J., et al., 2004). Colorectal cancer is the third most 
commonly diagnosed cancer both in men and women and the second most common cause of 
cancer related deaths in the United States, with an estimated 143,460 new cases and about 51,690 
deaths in 2012. More than 1.1 million Americans are living with current or past diagnosis of 
colorectal cancer (American Cancer Society, 2011-2013). Lifetime risk of developing colon 
cancer is about 1 in 20 for both men and women in the US (National Cancer Institute, 2011). 
Colon cancer originates from the inner lining of the colon mucosa. The tumor typically 
starts with a noncancerous polyp. A polyp is an abnormal growth of tissue that develops on the 
lining of the colon or rectum and that can become cancerous. Less than 10% of adenomas 
(certain types of polyps are called adenomas) progress to cancer (Levine J.S. and Ahnen D.J. 
2006). As cancer progresses, it grows larger in the lumen of the colon, but also grows outward 
through the other layers which compose the wall of the colon and invade other structures and it 
can spread to lymph nodes (Figure 1). Cancer cells can also be carried away by blood to other 
organs such as liver or lungs. Metastasis is the process by which cancer cells travel to distant 
parts of the body through blood or lymphatic vessels (American Cancer Society, 2011-2013). 
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Figure 1. Colorectal cancer growth (The website of the National Cancer Institute,  
(http://www.cancer.gov)). 
1.1.1.1. Colorectal cancer prevention 
     Even though the exact reason for most of the colorectal cancers is unknown, it is possible 
to prevent many of them. A minimum of 6 out of every 10 deaths due to colorectal cancer could 
be prevented if all men and women aged 50 years or older were screened routinely (Whitlock 
E.P., et al., 2008).  
The American Cancer Society (ACS) recommendations for early detection, followed by 
prevention of colorectal cancer are:  
i. Regular colorectal cancer screening is one of the most important recommendations from 
ACS to prevent colorectal cancer. People without any known risk factors should begin 
their regular screening at 50 years of age. People with a family history or other risk 
factors for colorectal polyps or cancer, such as inflammatory bowel disease, should 
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discuss with their doctor about early screening at a younger age and also screening more 
frequently. 
ii. Healthy weight maintenance by adopting a physically active lifestyle and consuming a 
healthy diet with more emphasis on plant sources. Colon cancer rates are high in 
populations with high total fat intakes and are lower in those consuming less fat. Diets 
high in vegetables, fruits, and whole grains have been linked with a decreased risk of 
colorectal cancer. Avoiding diets high in red meats (beef, lamb) and processed meats (hot 
dogs) also decreases colorectal cancer risk (Rose D. P., et al., 1986). 
iii. Decreasing alcohol consumption to no more than 2 drinks per day for men and 1 drink 
per day for women. A large cohort study reported a dose-response relationship between 
alcohol consumption and death due to colorectal cancer, with a Relative Risk of 1.2 (95% 
CI, 1.0–1.5) for four or more alcohol drinks per day compared with nondrinkers (Thun 
M. J., et al., 1997). 
iv. Taking vitamins and calcium: Some studies have suggested that taking a daily multi-
vitamin may lower colorectal cancer risk, but not all studies have confirmed this finding. 
More research is needed in this area (Giovannucci E., et al., 1998). 
1.1.1.2. Colorectal cancer treatment (National Cancer Institute) 
     Different types of treatment options are available for patients with colorectal cancer, 
some are standard currently using treatments and some are being tested in clinical trials.  
 Standard treatment options 
 Surgery: The most common treatment for all colon cancer stages is surgery. If 
the cancer is detected at an early stage, a local excision is performed to remove it 
without cutting through the abdominal wall. A polypectomy (surgical procedure 
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to remove polyps) is performed if the cancer is found in a polyp (early stage of 
colon cancer) form. If the cancer is found at a later stage, partial colectomy is 
performed (removing the cancer and a small amount of healthy tissue around it) 
followed by sewing the healthy parts of the colon together (anastomosis). Lymph 
nodes near the tumor area are removed and observed under a microscope to see 
whether the cancer has metastasized. If the two ends of the colon are not able to 
be sewed back together, an opening (called stoma) is made on the outside of the 
body for waste to pass through. This entire procedure is called a colostomy. A bag 
is placed around the stoma to collect the waste. Colostomy sometimes is 
temporary (until the lower colon has healed), and then it can be reversed. 
However, the colostomy may be permanent if the entire lower colon is removed 
due to cancer. Chemotherapy or radiation therapy (as an adjuvant therapy) is 
advised after surgery to kill any cancer cells that are left inside the body or to 
lower the risk of reoccurrence of cancer.  
 Chemotherapy: Treatment of colorectal cancer with anti-cancer drugs to stop 
the growth of cancer cells. Mechanism of these anti-cancer drugs is either by 
killing the cells or by stopping them from dividing. Depending on the stage and 
type of cancer, chemotherapy is given in various ways.  
o Systemic chemotherapy: Where anti-cancer drugs are injected into a vein, 
muscle or given by mouth. These drugs enter the bloodstream and can reach 
cancer cells present throughout the body. This treatment is recommended for 
metastasized cancers. The most commonly used drugs for colorectal cancer 
treatment are: Oxaliplatin, 5-Fluorouracil (5-FU), Capecitabine and 
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Irinotecan. Mostly, 2 or more of these drugs are combined for effective 
treatment. Adding Oxaliplatin to a regimen of 5-FU and Lecovorin 
significantly improved 5-year disease free survival (DFS) and 6-year overall 
survival (OS) in the adjuvant treatment of stage II or III colon cancer. These 
results also suggested that adjuvant oxaliplatin plus FU and leucovorin 
therapy is useful after surgery for patients with stage III colon cancer (Andre 
T., et al., 2009). 
o Regional chemotherapy: In this case, anti-cancer drugs are injected 
directly into the cerebrospinal fluid, an artery leading to a part of the body 
containing a tumor. This approach concentrates the dose of the drug and 
affects mainly cancer cells in those areas. It reduces severe side effects by 
limiting the amount of drug reaching the rest of the body. Hepatic artery 
infusion or chemoembolization is performed to treat cancer that has spread 
to the liver. This procedure is performed by blocking the hepatic artery and 
injecting chemotherapeutic drug between the blockage and the liver. This 
type of regional chemotherapy is used for colon cancer that has metastasized 
to the liver 
 Radiation therapy: Radiation therapy uses high-energy X-rays or other types of 
radiation to destroy cancer cells. It is often given along with chemotherapy. 
These two treatments together are known as chemoradiotherapy. 
Chemoradiotherapy is more effective against some colorectal cancers. 
Depending on the type and stage of the cancer, either external or internal 
radiation therapy is performed. 
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o External radiation therapy is most commonly used in colorectal cancer 
patients and it uses a machine outside the body to send radiation towards the 
cancer site.  
o Internal radiation therapy or Brachytherapy uses small pellets of 
radioactive substance placed directly into or near the cancer. The radiation 
travels only a short distance, limiting the adverse effects on surrounding 
healthy tissues. 
 Targeted therapy:  Targeted therapy uses drugs or other substances to stop the 
growth and spread of cancer by interfering with specific molecules, which are 
involved in cancer growth and progression. Targeted cancer therapy is less harmful 
to normal cells. Monoclonal antibody therapy is a type of targeted therapy used to 
treat colon cancer. Monoclonal antibodies bind to specific targets on cancer cells 
and stop their growth, or keep them  from spreading. Bevacizumab (Hurwitz H., 
et al., 2004), Cetuximab (Cunningham D., et al., 2004) and Panitumumab (Gibson 
T. B., et al., 2006) are most commonly used targeted therapy drugs in colorectal 
cancer treatment. These drugs target the vascular endothelial growth factor 
(VEGF), VEGF stimulates angiogenesis in a variety of diseases, especially in 
cancer. Over the past decade, life expectancy in patients with metastatic colorectal 
cancer has changed dramatically with the help of molecularly targeted agents. 
Novel molecular targeted therapy drugs, Ziv-Aflibercept and Regorafenib were 
recently approved by the U.S. Food and Drug Administration (FDA) to treat 
metastatic colorectal cancer patients. These anti-angiogenic drugs improved the 
survival of metastatic colorectal cancer patients (Jitawatanarat P., Wee W., 2013). 
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1.1.1.3. Major risk factors of colorectal cancer (American Cancer Society, 2011-2013) 
Age: The risk of developing colorectal cancer increases with advancing age, younger 
adults can develop colorectal cancer, but the chances increase significantly after age 50. More 
than 90% of colorectal cancer cases occur in people with 50 years of age or older. Many 
epidemiological and experimental studies suggest an association between decreased vitamin D 
levels and increased risk of various cancers, the evidence is more significant for colorectal 
cancer (Garland C.F., et al., 2009; Yin L., et al., 2009; Wu K., et al., 2007; Gorham E. D., et al., 
2007; Giovannucci E., 2007; Lin J., et al., 2005; Huncharek M., et al., 2009; Bertone-Johnson E. 
R., et al., 2005; Garland C.F., et al., 2007;  Lin J., et al., 2007; Robien K., et al., 2007; Freedman 
D.M., et al., 2008). Older people are at a greater risk of developing vitamin D deficiency, 
because of changes in lifestyle like clothing and outdoor activity (Photochemical synthesis of 
vitamin D is the major source of vitamin D). Older people also suffer additional mobility 
restrictions. Aging is also associated with a decreased ability to make precursor of vitamin D3 in 
the skin and renal production of calcitriol (active form of vitamin D) also decreases because of 
diminished renal function at old age (Holick, M.F., et al., 1989; Lau K.-H.W. & Baylink, 
D.J.1999). 
Gender: Colorectal cancer is more predominant in males than in females, but common in 
both men and women (Fatime A.H., and Robin P.B. 2009). 
Race and Ethnicity: African Americans have the highest colorectal cancer incidence and 
mortality rates, when compared to all other racial groups in the United States. It was reported 
earlier that the African Americans have wide spread vitamin D deficiency, due to higher degree 
of melatonin in their skin (Clemens T.L., et al., 1982; Marilyn T., et al., 2009; and Harri S.S. and 
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Dawson-Hughes B., 1998). Highest colorectal cancer risk is also observed in Ashkenazi Jews of 
Eastern European descent, compared to any ethnic group in the world (Feldman G.E. 2001). 
Personal or family history of colorectal cancer: Personal history of adenomatous 
polyps, inflammatory bowel disease (Bernstein C.N., et al., 2001) or colon cancer increases the 
risk of colorectal cancer incidence. Most of the colorectal cancer cases are observed in people 
without a family history of colorectal cancer. But, about 20% who develop colorectal cancer 
have a close relative(s) who have been affected by this disease. People with a history of 
colorectal cancer or adenomatous polyps in their first-degree relatives (parents, siblings, or 
children) are at a greater risk in developing the disease (Lynch H.T. and de la Chapelle A., 
2003). 
1.1.2. Vitamin D 
Vitamin D is a fat-soluble pro-hormone that is present in very few diets like cod liver oil, 
fish, eggs, milk and vitamin D fortified foods. Vitamin D is also produced endogenously when 
ultraviolet rays from sunlight converts 7-dehydroxycholesterol in the skin to cholecalciferol 
(vitamin D3). Vitamin D obtained from sun exposure and food sources is biologically inactive 
and must undergo two hydroxylation steps in the body for activation. Vitamin D is first 
hydroxylated in the liver by an enzyme 25-hydroxylase (CYP27A1) to produce 25-hydroxy 
vitamin D or also known as calcidiol. Calcidiol is further hydroxylated in the kidney by an 
enzyme 1α-hydroxylase (CYP27B1) to produce biologically active 1α, 25-Dihydroxyvitamin D3 
or also known as Calcitriol (Feldman D., et al., 2008). 
Vitamin D produces its biological effects by binding to vitamin D receptor (VDR).  VDR 
expression has been identified in almost every human tissue. 1, 25(OH)2 vitamin D3 is a flexible 
molecule as shown in Figure 2, and it can rotate around its single carbon bond positioned at 6,7 
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and generate a wide array of ligand shapes ranging from 6-s-cis (6C) to 6-s-trans (6T). 
Depending on the ligand configuration, it binds to either cell membrane receptor (VDRmem) or 
cytosolic/nucleus receptor (VDRnuc). 6C configuration of vitamin D preferentially mediates 
rapid, non-genomic (seconds-minutes-hours) effects that include the opening of voltage gated 
channels like Ca
2+
 and Cl
-
, 6T configuration of vitamin D favors slow, genomic (hours-days) 
responses (Anthony W. et al., 2001 and Norman A.W. 2005). Upon binding to VDR, 1α,25-
Dihydroxyvitamin D3 heterodimerizes with retinoid X receptors (RXR). This complex then 
binds to a small sequence of DNA called vitamin D response element (VDRE) present in the 
promoters of many genes it regulates. A variety of additional proteins called coactivators, 
complex with the activated VDR/RXR heterodimers and help in recruitment of histone acetyl 
transferases (HAT), and allowing transcription to proceed.  
         
 
 
 
        
       Figure 2. 6-s-cis conformation and 6-s-trans conformation of 1α,25(OH)2 vitamin D3  
      (Norman A.W. 2005). 
In addition to coactivators there are a number of corepressors, which act by recruiting 
histone deacetylases (HDAC) to the gene which reverses the actions of HAT, leading to a 
reduction in access to the gene by the transcription process. Coactivators and corepressors are 
specific for different genes, so various cell types differentially express these coregulators 
(McKenna N.J., et al., 1999, McKenna et al., 2002 and Murayama A., et al., 2004). 
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1.1.2.1. Vitamin D and mortality 
The World Health Organization estimates that 61% of male deaths and 65% of female 
deaths throughout the world are correlated with low blood levels of serum 25-hydroxyvitamin D 
(25(OH)D). The top 6 causes of deaths (cardiovascular disease, cancer, respiratory infection, 
respiratory disease, tuberculosis and diabetes mellitus) are related to low vitamin D levels (Grant 
W.B., et al., 2011). 
1.1.2.2. Vitamin D and colorectal cancer 
African-Americans have higher incidence and mortality from colorectal cancer (CRC) 
than white Americans, due to their significantly lower mean serum levels of vitamin D (Jemal 
A., et al., 2009; Irby K., et al., 2006). Colorectal cancer mortality rates in African Americans 
were 44% higher than in white Americans (Altekruse S., et al., 2010).  Many epidemiological 
and experimental studies support a protective action of vitamin D against colon cancer. Vitamin 
D slows down the progression of colon cancer cells from premalignant to malignant states, 
keeping their proliferation in check (Garland C. F. and Garland F. C. 1980; Garland C.F., et al., 
1989; Freedman D. M., et al., 2002). Researchers found that people with the highest pre-cancer 
circulating vitamin D levels (100 nM per liter of blood or higher) were nearly 40 percent less 
likely to develop colon cancer than those with the lowest levels (less than 25 nM per liter) (Jenab 
M., et al., 2010).  
Several studies have reported that the anti-tumoral action of calcitriol (the active from of 
vitamin D) in CRC depends on various mechanisms such as inhibition of cell proliferation and 
angiogenesis, sensitization to apoptosis, induction of epithelial cell differentiation and cell 
detoxification metabolism. Calcitriol induces the expression of p21 and p27 (cyclin-dependent 
kinase inhibitors), and represses the expression of cyclin A and cyclin F (Palmer H.G., et al., 
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2003, Fernandez-Garcia N.I., et al., 2005). Calcitriol sensitizes colorectal cancer cells to 
apoptosis by up-regulating the proapoptotic protein BAK1, and down-regulating the anti-
apoptotic protein BAG1 (Diaz G.D., et al., 2000, Barnes J.D., et al., 2005). Calcitriol also 
increases the expression of occludin, E-cadherin, and plectin levels, which are essential in 
maintaining the epithelial phenotype (Palmer H.G., et al., 2003 and Palmer H.G., et al., 2001). 
The combined effect of all these mechanisms may determine the anti-tumoral action of calcitriol 
(Larriba M.J., et al., 2008 and Krishnan A.V., Feldman D., 2011). Colorectal cancers arise due to 
the accumulation of genetic and epigenetic changes, which in turn induce the malignant 
progression of colon epithelial cells (Pereira F., et al., 2012),  the study of epigenetic 
mechanisms of calcitriol to suppress the colon cancer growth remains an active area of 
investigation. 
1.1.3. Epigenetics 
 For many years, colon cancer research was mainly focused on genetic alterations, and 
changes in the DNA sequence is the best known genetic alteration. In recent years, due to major 
advances in understanding molecular pathogenesis of colon cancer, attention has been focused 
on epigenetic alterations. Epigenetics is defined as heritable changes in gene expression without 
a change in the DNA sequence (Egger G., et al., 2004). The term “epigenetics” was coined by 
Conrad H. Waddington in the year 1942 in reference to the study of “causal mechanisms by 
which the genes of the genotype bring about phenotypic effects” (Waddington C., 1942). 
However, in the year 2009 Alexander Vargas, an evolutionary developmental biologist from 
University of Chile suggested that Paul Kammerer's experiments, performed back in the early 
1900s, revealed signs of what are now well-known epigenetic effects (Vargas A. O., 2009). 
Epigenetic changes include histone modifications, DNA methylation and RNA-mediated 
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silencing (Herceg Z. and Hainaut P., 2007). DNA methylation is a well-known epigenetic 
marker, and global hypomethylation was the first epigenetic change to be identified in cancer 
cells (Feinberg A. P., Vogelstein B., 1983). 
1.1.3.1. DNA methylation 
DNA methylation is a process of chemical modification used by mammalian cells to 
maintain a normal gene expression pattern. DNA methylation is mediated by DNA methyl 
transferases (DNMTs), which is an enzymatic addition of a methyl group to the 5’position of a 
cytosine ring (Figure 3, Takai D and Jones P. A., 2002). CG dinucleotide sequence (CpG) is the 
most favorable substrate for DNMTs.  In mammalian cells, most of the CpGs are methylated, the 
unmethylated CpGs are typically present in regions of DNA that are called CpG islands. A CpG 
island is defined as a sequence of minimum 200 base pairs in length with more than 50% CG 
content and an observed to expected ratio of CpG more than 60 % (Gardiner-Garden M and 
Frommer M., 1987 & Lao V. V. and Grady W. M., 2011). 
                              
          
 
 
          
         Figure 3. DNA methylation involves the addition of a methyl group onto the 5 position  
         of a cytosine residue, mediated by the enzymes DNMTs (Takai D. and Jones P.A., 2002). 
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1.1.3.1.1. DNA methylation and colorectal cancer 
 Generally, CpG islands remain unmethylated, whereas the sporadic CpG sites in the 
rest of the genome are methylated. During aging, this pattern is gradually reversed and leads to 
sporadic methylation in the CpG islands and a global hypomethylation, but this change is more 
prominent during cancer development (Egger G., et al., 2004 and Bird A., 2002).  Several genes 
affected by hypermethylation are involved in cell cycle regulation, cell adhesion, apoptosis, 
angiogenesis, invasion and metastasis (Table 1). CpG island methylation in promoter regions is 
often associated with silencing of tumor suppressor genes and there are evidences suggesting that 
the aberrant DNA methylation occurs in most cancers, including colorectal cancers (Toyota M., 
et al., 1999 and Jones P. A., Baylin S. B., 2002).  
Figure 4. DNA methylation in normal colon and colorectal cancer (Goel A. and  
Boland C.R., 2012). 
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                 In normal colon, CpG islands within the promoter of a tumor suppressor gene are 
generally unmethylated (blue circles), whereas the CpG repeats within the gene body are frequently 
methylated (black circles). This permits easy access by transcription factors and RNA polymerase II 
to bind to the gene promoter and activates the gene expression. In colorectal cancer, DNA methyla 
transferase (DNMT), Histone deacetylase (HDAC), and methyl binding protein (MBP) complex 
catalyze the transfer of methyl groups to cytosines in the promoter CpG sites, resulting in the 
hypermethylation induced transcriptional silencing of the tumor suppressor genes (Figure 4, Goel A. 
and Boland C.R., 2012). 
1.1.3.2. Histone modification and chromatin remodeling 
               The nucleosome is the basic unit of chromatin structure, composed of approximately 200 
base pairs of DNA tightly wrapped around the cylindrical histone octamer. Histone octamer consists 
of two molecules of each of the four core histones, H2A, H2B, H3, and H4. The linker histone, H1 
plays an important role in linking the nucleosome structures together to further condense the 
chromatin (Thomas J. O., Kornberg R. D., 1975 and Luger K., et. al 1997). The four core histones 
consist of a globular C-terminal domain and an unstructured N-terminal tail. Histone N-terminal tail 
that protrude from the histone octamer are frequently targeted by various posttranslational 
modifications, (Kouzarides T., 2007; Santos-Rosa H., and Caldas C., 2005; Peterson C. L., and 
Laniel, M. A., 2004;   Bhaumik S. R., et al., 2007) and some of these modifications are 
enzymatically reversible (Shi Y., and Whetstine J. R., 2007). The biological significance of all these 
histone modifications is not clearly understood, but the modifications are known to influence 
transcription, DNA repair, DNA replication and chromatin condensation.
  
 
            Table 1. Genes commonly methylated and suppressed in colorectal cancer. 
 
Gene Protein Purpose Function/Pathway Colorectal 
neoplasia 
Methylation 
frequency 
(%) colon 
cancer 
Reference 
APC 
 
 
HLTF 
 
 
CDH1 
 
 
VIM 
 
 
CDKN2
A/p16 
 
Adenomatous 
polyposis coli 
 
Helicase-like 
transcription 
factor 
E-cadherin 
 
 
Vimentin 
 
 
Cyclin-
dependent kinase 
inhibitor 2A 
Diagnosis 
 
 
Prognosis 
 
 
- 
 
 
Diagnosis 
 
 
Diagnosis 
 
Inhibits Wnt signaling 
pathway 
 
Chromatin remodeling 
factor 
 
Cell adhesion: Invasion 
and Metastasis 
 
Cytoskeleton 
stabilization /  
 
Epithelial-Mesenchymal 
Transition (EMT) 
Cell cycle regulation 
Hypermethylated 
 
 
Hypermethylated 
 
 
Hypermethylated 
 
 
Hypermethylated 
 
 
Hypermethylated 
10-30 
 
 
30-50 
 
 
30-55 
 
 
50-80 
 
 
20-30 
Lee et al., 2009; Deng 
et al., 2004; Esteller et 
al., 2000 
Wallner et al., 2006; 
Herbst et al., 2009 
 
Wheeler et al., 2001 
 
 
Chen  et al., 2005; 
Ahlquist et al., 2012 
 
Zou et al., 2002; 
Nakayama et al., 2010 
 
1
5
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The impact of histone modification on chromatin structure is governed by the type of 
modification and the specific amino acid involved in the modification (Table 2).  For example, 
lysine acetylation is associated with transcriptionally active DNA (euchromatin), whereas the 
effects of lysine and arginine methylation vary by location of the amino acid and number of 
methyl groups on these residues (Fischle W., 2003; Pray-Grant M.G., et al., 2005; Covic M., at 
al., 2005). 
                        Table 2. Types of histone modification. 
 
 
 
 
 
 
 
 
 
1.1.3.2.1. Histone modification in colorectal cancer 
Histone methylation is recognized as an important histone modification linked to both 
transcriptional activation and repression depending on the specific amino acid affected (Martin 
C., and Zhang Y., 2005). A well-studied type of histone methylation is methylation of lysine 
residues, which is conferred by histone methyltransferases (HMTs). More than twenty lysine and 
arginine HMTs have been identified. HMTs either act alone or in complex with other HMTs in 
order to catalyze site-specific histone methylation. Histone methylation is not only important for 
Amino Acid Modification 
Lysine Methylation, Acetylation, 
Ubiquitination, 
Sumoylation, 
ADP-Ribosylation 
Arginine Methylation 
Serine Phosphorylation 
Threonine Phosphorylation 
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normal development and differentiation, but is also associated with tumor initiation and 
development. For example, histone-lysine N-methyltransferase, EZH2 (Enhancer of Zeste 
Homologue 2, an HMTase) was found to be overexpressed in colon cancer (Bracken A.P. and 
Helin K., 2009; Ougolkov A.V., et al., 2008).  
There are three possible states of lysine methylation, namely, mono, di, and 
trimethylation. The methyl groups on the lysine residues can be removed by histone 
demethylases. Two families of histone demethylases have been identified, including flavin 
adenine dinucleotide dependent family and the jumonji C domain containing family (Lim S., et 
al., 2010 and Tsukada Y., et al., 2006). The JmjC family of histone demethylases consists of 
approximately 30 members within the human genome (Klose R., 2006). Jumonji domain 
containing 1A (JMJD1A) is a member of the jumonji C domain containing 1A family and 
responsible for demethylation of mono- and dimethylated H3K9 (Yamane K., et al., 2006). 
Histone demethylase JMJD1A has been shown to be upregulated in hypoxic conditions via 
hypoxia inducible factor-1-alpha (HIF-1α). 
Hypoxia is a common characteristic of many solid tumors such as prostate cancer, breast 
cancer and colon cancer. Hypoxia occurs when the demands of growth and metabolism of a 
tissue or organ surpass the vascular oxygen supply (Wellmann S., 2008). Recent studies have 
shown that cellular hypoxia in colon cancer cells stabilizes HIF-1α, thereby increasing histone 
demethylase JMJD1A levels. Increased JMJD1A expression decreases the H3K9Me2 
methylation on the promoters of target genes such as adrenomedullin (ADM) and the growth and 
differentiation factor 15 (GDF15), thereby modulating tumor growth (Figure 5, Krieg A. J., et 
al., 2010 and Mamoru U., et al., 2010). 
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Figure 5. JMJD1A action during hypoxia (Krieg A. J., et al., 2010).   
 
1.1.3.3. Noncoding microRNAs (miRNAs) 
Changes in the expression profiles of miRNAs have been observed in a variety of human 
tumors, including colon cancers (Wong J. J., et al., 2007 and Slaby O., et al., 2009). MiRNAs are 
small non-coding RNAs about 19-25 nucleotides long. The miRNAs are transcribed from their 
genes by RNA Polymerase II (Pol II) as long primary miRNAs (Cai X., et al., 2004 and Lee Y., 
et al., 2004) and processed into 60-70 nucleotide-long precursor miRNAs by Drosha  (RNase III 
endonuclease) and a RNA binding protein Pasha (Figure 6). The precursor miRNAs are exported 
to the cytoplasm by a Ran GTP/Exportin 5 – dependent mechanism (Bohnsack M. T., et al., 
2004; Lee Y., et al., 2003; Zeng Y., and Cullen B. R., 2004). In the cytoplasm, they are further 
processed into 19-25 nucleotides long mature miRNAs by the RNase III protein Dicer (Esquela-
Kerscher A., and Slack F. J., 2006; Lee Y., et al., 2002). These mature miRNAs are incorporated 
into the RNA-induced silencing complex (RISC) to recognize and bind to target mRNAs 
(Filipowicz W., et al., 2008).  
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Figure 6. MiRNA biogenesis (He L., Hannon GJ., 2004). 
MiRNAs regulate gene expression by targeting mRNAs and by associating with the 3’-
untranslated region (UTR) through complementary base pairing (Bartel D. P., 2004), and this 
leads to either degradation or translational suppression of their target genes depending on the 
degree of complementarity (Figure 6). Each miRNA is predicted to have several targets, and 
each mRNA may be regulated by several miRNAs, which makes them master regulators of gene 
expression (Rajewsky N., 2006; Lewis B.P., et al., 2003; Lim L. P., et al., 2005). MiRNAs have 
Polymerase II 
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been implicated in regulation of important processes like cell proliferation (Cheng A. M., et al., 
2005), apoptosis (Xu P., et al., 2004), differentiation (Karp X., and Ambros V., 2005), 
development (Chen C., et al., 2004), metabolism (Poy M., et al., 2004), invasion and metastasis 
(Ma L., et al., 2007). 
1.1.3.3.1. Epigenetic dysregulation of miRNAs expression in colorectal cancer 
Nearly, a total of 160 miRNAs are found to be dysregulated in colorectal cancer (Luo X., 
et al., 2011). The mechanisms responsible for miRNAs dysregulation in human cancers are still 
poorly understood. One mechanism that is best-characterized is aberrant methylation of the 
miRNA gene promoters in various tumors, including colorectal cancer (Lopez-Serra P., and 
Esteller M., 2011; Tang J.T., et al., 2011). An important study of genomic sequencing of miRNA 
genes revealed that nearly fifty percent of miRNAs are associated with CpG islands (Weber B., 
et al., 2007). MiR-34b and miR-34C, TP53 pathway components, are found to be epigenetically 
silenced in colorectal cancer. Treatment with 5-aza-2’-deoxycytidine (demethylating agent) has 
been shown to restore the expression of miR-34b and miR-34c (Toyota M., et al., 2008). The two 
miRNAs miR-143 and miR-145 were found to be downregulated in colorectal adenomas/cancers 
compared to normal colon (Michael M.Z., et al., 2003; Cummins J. M., et al., 2006) and to play 
the role of tumor suppressor (Bandres E., et al., 2006; Schepeler T., et al., 2008; Wang C. J., et 
al., 2009). The mir-143BP is a chemically modified miR-143 with improved nuclease resistance, 
and has been used as therapeutic drug for colorectal cancer treatment (Kitade Y., and Akao Y., 
2010).  
The introduction of high-throughput microarray-based miRNA expression profiling 
radically changed the field of miRNA expression pattern analysis. The list of differentially 
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expressed miRNAs is growing steadily, a list of important miRNAs and their target genes 
involved in colorectal carcinogenesis is shown in Table 3.    
  Table 3. List of microRNAs and their gene targets involved in colorectal cancer pathogenesis. 
 
miRNA Up-regulated / 
Down-regulated 
in CRC 
Target Gene Reference 
miR-20a 
 
 
miR-21 
 
 
 
 
miR-31 
 
miR-
34a/b/c 
 
miR-143 
 
 
 
miR-145 
 
Up-regulated 
 
 
Up-regulated 
 
 
 
 
Up-regulated 
 
Down-regulated 
 
 
Down-regulated 
 
 
 
Down-regulated 
PTEN, RUNX1, 
TP53INP1 
 
PTEN, TIMP3, 
PDCD4, RECK, 
TPM1, SPRY2 
 
 
BMP2 
 
CDK4, CDK6, 
E2F3, CyclinE2 
 
KRAS, p53, 
DNMT3a, ERK5 
 
 
cMYC, STAT1, 
OCT4, SOX, p53, 
IRS-1, YES1, KLF4 
Motoyama et al., 2009 
 
 
Schetter et al., 2008; Schmitz et al., 
2009; Yamamichi et al., 2009; Kumar 
et al., 2007; Gabriely et al., 2008; Zhu 
et al., 2007; Sayed et al., 2008 
 
Motoyama et al., 2009 
 
Toyota et al., 2008; Raver-Shapira et 
al., 2007 
 
Wang et al., 2009; Suzuki et al., 
2009; Akao et al., 2007; Chen et al., 
2009; Ng et al., 2009 
 
Wang et al., 2009; La et al., 2009; 
Suzuki et al., 2009; Sachdeva et al., 
2009; Gregersen et al., 2010; Xu et 
al., 2009 
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Changes in the expression of proteins, which are involved in miRNA processing is also 
another possible reason for the miRNA dysregulation in colorectal cancer. For example up-
regulation of the mRNA levels of Drosha, Dicer and Ago2 have been reported in certain 
colorectal cancer (Papachristou D. J., et al., 2011). 
 
1.2. Objective and specific aims 
1.2.1. Objective of the study 
 The main goal of this study was to determine the epigenetic mechanisms of how calcitriol 
(active form of vitamin D) suppresses the proliferation of colon cancer cells and the growth of 
tumor xenografts in nude mice.  
Colon cancer is the second most common cause of cancer related deaths in the United 
States. Many epidemiological and experimental studies have supported a protective action of 
calcitriol against colon cancer. Researchers found that people with high circulating vitamin D 
levels (100 nM or higher) were nearly 40 percent less likely to develop colon cancer than those 
with low levels (less than 25 nM). However, the mechanism of how calcitriol suppresses colon 
cancer remains to be understood. We have focused on the novel epigenetic mechanisms of the 
antitumor activity of calcitriol in colon cancer. We have identified miR-627 as the only 
microRNA whose expression is induced by calcitriol in colon cancer cells in vitro and in vivo in 
tumor xenografts. We have also identified that histone demethylase Jumonji domain containing 
1A (JMJD1A) is a potential target of miR-627. It has been recently reported that JMJD1A is 
upregulated in colon cancer during hypoxia (a low oxygen condition exists in the center of solid 
tumors). Increased JMJD1A expression decreases the histone methylation on the promoters of 
target genes such as adrenomedullin (ADM) and the growth and differentiation factor 15 
 23 
 
(GDF15) and increases their expression, which promotes tumor growth. By inhibiting JMJD1A, 
we have shown that miR-627 suppresses colon cancer growth.  
This study is important because the results will help us to understand the mechanism of 
action of calcitriol in colon cancer. Although calcitriol has excellent antitumor activity, its side 
effect of inducing hypercalcemia prevents its use in the clinical treatment of cancer. This study 
has the potential to identify the novel targets (miR-627 and JMJD1A) downstream of calcitriol, 
which can be used to design new therapy for colon cancer while bypassing the hypercalcemic 
toxicity. Our study is innovative because this is the first study of microRNA in the antitumor 
action of calcitriol, the function of miR-627 has not been studied before. The regulation of 
JMJD1A by calcitriol through miR-627 is also a novel mechanism.  
In this study, we hypothesize that miR-627 may play an important role in growth 
inhibition induced by calcitriol and JMJD1A may be a potential therapeutic target to treat colon 
cancer. 
1.2.2. Specific aims 
To test our hypothesis, we propose the following specific aims: 
1.2.2.1. Specific aim 1: To determine the role of miR-627 in colon cancer suppression by 
calcitriol in vitro 
The working hypothesis was that calcitriol induces miR-627 expression in colon cancer 
cells. MicroRNA-627 would in turn inhibit JMJD1A expression and this would make colon 
cancer cells susceptible to calcitriol induced growth inhibition. The experimental design for this 
part of the study was:  
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a) MicroRNA expression profiling in control and calcitriol (100nM) treated HT-29 cells 
using the Ambion mirVana miRNA Bioarray. The upregulation of miR-627 by calcitriol 
was confirmed by real-time PCR in HT-29 and HCT-116 cells. 
b) To determine the effect of miR-627 on HCT-116 colon cancer cell proliferation by WST-
1 assay. 
c) To determine the VDR requirement for activation of miR-627 expression in calcitriol 
treated SW-620 cells. 
d) To determine the potential target of miR-627 and its expression in calcitriol treated colon 
cancer cells. 
e) To determine the effect of JMJD1A expression on HCT-116 colon cancer cell 
proliferation by WST-1 assay. 
f) To determine the effect of calcitriol induced miR-627, on H3K9Me2 levels on the 
promoters of JMJD1A targets genes, such as GDF 15. 
1.2.2.2. Specific aim 2: To determine the role of miR-627 on the in vivo growth of colon 
cancer xenografts 
The working hypothesis was that miR-627 overexpression in colon cancer xenografts will 
inhibit JMJD1A expression and this would in turn decrease the growth of the colon cancer 
xenografts. The experimental design for this part of the study was:  
a) To determine the expression of miR-627 and JMJD1A in calcitriol treated HT-29 tumor 
xenografts. 
b) To determine the effect of calcitriol on the growth of HCT-116 and HT-29 colon tumor 
xenografts. 
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c) To determine the effect of calcitriol on the growth of HCT-116-JMJD1A-3’UTR colon 
tumor xenografts, after blocking the activity of miR-627 by overexpressing the JMJD1A 
3’UTR sponge. 
d) To determine the effect of calcitriol on the growth of HCT-116-JMJD1A-3’UTR-MUT 
colon tumor xenografts, when the miR-627 binding site within the 3’UTR sequence was 
mutated.  
e) To determine the effect of miR-627 on the growth of colon tumor xenografts: Comparing 
the tumor growth in HCT-116 cells stably expressing miR-627 or miR-NC. 
1.2.2.3. Specific aim 3: To determine miR-627 expression in human colon cancer specimens 
The working hypothesis was that miR-627 expression will be downregulated in human 
colon cancer specimens compared to normal colon tissues. Decreased miR-627 expression would 
in turn increase the JMJD1A expression in human colon cancer specimens, which will stimulate 
colon cancer growth. The experimental design for this part of the study was: 
a) To determine the expression levels of miR-627 in human colon cancer specimens by 
Real-Time PCR.  
1.3. Materials and methods 
1.3.1. Cell lines used 
The human colon cancer cell lines HCT-116, HT-29 and SW-620 were purchased from 
American Type Culture Collection (ATCC). HCT-116 cells were cultured in RPMI-1640 
medium (Hyclone, Thermo scientific) containing 10% fetal bovine serum (FBS). HT-29 and 
SW-620 cells were cultured in DMEM medium (Hyclone, Thermo Scientific) containing 10% 
FBS. 
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1.3.2. Drugs and chemicals 
Calcitriol (1α, 25-dihydroxy vitamin D3, the active form of vitamin D) was purchased 
from Cayman Chemical (Ann Arbor, MI). Formaldehyde was purchased from Alfa Aesar (Ward 
Hill, MA). BrdU (5-Bromodeoxyuridine, Product No: B9285) was purchased from Sigma-
Aldrich (St. Louis, MO). Propidium Iodide (PI, Cat# 10009957) was purchased from Cayman 
chemical company.  10mM concentration of Calcitriol was prepared in DMSO and then finally 
diluted 100X in media to treat colon cancer cell lines at desired concentrations.  
1.3.3. Western blot analysis 
 Cells were lysed in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS in 
PBS). Complete protease inhibitor cocktail (Roche) was added to lysis buffer before use. Protein 
concentration was determined by Bio-Rad DC protein assay (Bio-Rad). Protein samples were 
subjected to SDS-PAGE and transferred to nitrocellulose membrane. The membrane was 
blocked in 5% non-fat milk in PBS overnight and incubated with primary antibody and 
subsequently with appropriate horse radish peroxidase-conjugated secondary antibody. Signals 
were developed with ECL reagents (Pierce) and exposure to X-ray films. Anti-JMJD1A 
polyclonal antibody was kindly provided by Dr. Doug Demetrick at University of Calgary. Anti-
β-tubulin and anti-GFP antibodies were purchased from Santa Cruz Biotechnology. Anti-p15, 
p16, p21, and p27 antibodies were purchased from Cell Signaling Technology. 
1.3.4. Detection of apoptosis by flow cytometry 
 Colon cancer cells were harvested after desired treatment and washed in cold phosphate-
buffered saline (PBS). Cell density was measured using a hemocytometer and cells were 
resuspended in annexin-binding buffer to 1x10
6
 cells/mL. 5 µL Annexin V fluorescein conjugate 
(Alexa Fluor 647 purchased from Invitrogen) was added to 100 µL of cell suspension and cells 
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were incubated at room temperature (RT) for 15 minutes. After the incubation period, 400 µL of 
annexin-binding buffer was added to the cell suspension, gently mixed and cells were analyzed 
immediately by an Accuri C6 Flow Cytometer. 
1.3.5. Labeling cells with anti-BrdU and propidium iodide (PI) for flow cytometric analysis 
For in vitro labeling of BrdU, HCT-116 colon cancer cells were treated with calcitriol for 
72 hrs, BrdU was dissolved in PBS and added to culture medium directly to achieve a final 
concentration of 10µM. After incubating the cells with BrdU for 30 min at 37
0
C, the cells were 
washed with RPMI-1640 medium twice and were further incubated at 5% CO2 and 37
0
C. 0hrs, 
4hrs, 8hrs, 12hrs, and 6hrs after the BrdU pulse, cells were washed with PBS and fixed in 70% 
ice-cold ethanol and stored overnight at -20
0
C. Fixed cells were resuspended in 2N HCl-0.5% 
Triton X-100 solution and incubated for 30 min at RT, to separate the DNA from the cells. To 
remove the excess acid, the cells were washed twice with PBS and then resuspended in PBS-1% 
BSA-0.5% Tween 20 solution and hybridized with a mouse monoclonal anti-BrdU antibody 
conjugated to FITC (1:20 dilution, Enzo Life Sciences, ITEM NO: ALX-804-197L-T060) for 30 
min at RT in the dark. The cells were then washed with PBS-1%BSA-0.5%Tween20 (2X), 
resuspended in PBS and stained with PI (5µg/mL) for 30 min at RT in the dark. The cellular 
DNA content and the amount of BrdU incorporated were measured simultaneously using an 
Accuri C6 flow cytometer. Green fluorescent light emission (FITC=BrdU incorporation) was 
collected using FL1 and red fluorescence (PI=DNA content) was collected in FL3 detectors. 
Plots of BrdU labeling vs DNA content were drawn using FLOWJO software. 
1.3.6. WST-1 cell proliferation assay 
WST-1 reagent (Roche, Indianapolis, IN) was used to measure the relative proliferation 
rates of cells in culture medium. The principle of this assay is based on the conversion of the 
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tetrazolium salt, WST-1 (slightly red) into water soluble formazan dye (dark red) by 
mitochondrial dehydrogenase present only in viable cells. The activity of mitochondrial 
dehydrogenase increases proportionally with the number of viable cells, leading to an increase in 
the conversion of WST-1 to formazan dye. The resulting increased color intensity is in turn 
quantified by measuring the absorbance at 440 nm. Briefly, after treatment with calcitriol, the 
colon cancer cells were incubated with WST-1 for 4 hours at 37
o 
C in a humidified atmosphere 
maintained at 5 % CO2 as recommended by the manufacturer. The absorbance of the formazan 
dye was measured at 440nm. 
1.3.7. Microarray-miRNA expression profiling 
In order to identify the potential microRNAs that are differentially expressed in HT-29 
colon cancer cells following calcitriol treatment, we performed microarray-based miRNA 
expression profiling. Total RNA was isolated from the control and calcitriol (100 nM for 24 
hours) treated HT-29 cells using the mirVana miRNA Isolation Kit (Ambion). MicroRNAs were 
further concentrated using flashPAGE
TM
 Fractionator system (Ambion). A polynucleotide tail 
was added at the 3’end of these concentrated miRNA samples from control and calcitriol treated 
HT-29 cells. These concentrated miRNAs from control and calcitriol treated HT-29 cells were 
labeled with the mirVana miRNA Labeling kit (Ambion) using fluorescent dye-Cy3 and Cy5 
post labeling reactive dyes, respectively (Amersham Biosciences). Following this, the miRNA 
samples from the HT-29 cells were kept for overnight hybridization with the probes on the 
mirVana miRNA Bioarray slide. The array slides were scanned with an Aron 4000B Genepix 
Microarray Scanner and results were analyzed with Genepix software (Molecular Devices, 
Sunnyvale, CA, USA). To ensure accuracy, the labeled miRNA samples were hybridized in 
duplicate probes. The ratio of fluorescence intensity of calcitriol treated HT-29 cells over non 
 29 
 
treated HT-29 was calculated to determine the differential expression of the miRNAs in the two 
treatment groups.                   
    
 
 
 
 
 
 
 
 
 
 
 
Figure 7. MiRNA array procedure. (A) Amine NTPs are incorporated into purified miRNAs   
during tailing with poly (A) polymerase. MiRNAs are then labeled with amine reactive dyes. 
After hybridization with probes on a microarray slide, dye signals are analyzed. (B) Represent- 
-ative hybridization signals from a miRNA array procedure (Red: Cy3; Green: Cy5;  
  nt: nucleotide; Shingara J., et al., 2005). 
1.3.8. Real-time polymerase chain reaction 
The miRNA expression was measured by real-time PCR using TaqMan® MicroRNA 
assay (Cat # RT1560 for miR-627) from Applied Biosystems (Foster city, CA). Total RNA was 
isolated from colon cancer cells using mirVana™ miRNA Isolation Kit (Ambion). 5 μg of total 
MicroRNA 
21-22 nt long 
5’ 3’ 
5’ 
5’ 
 
 
 
UUUUUUUUUUUUU  3’ 
   *     *    *    *       * 
UUUUUUUUUUUUU  3’    
Label with Poly(A) Polymerase 
Incorporating aaUTP  */UTP mix. 
Couple Cye dye to aminoallyl UTP 
Hybridize overnight 
Probe sequence 
 
Analyze Cy3/Cy5 signal 
A. 
B. 
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RNA was used in reverse transcription reaction. The cDNA was used as template to perform 
PCR on an Applied Biosystems 7500 Real-time PCR System following the manufacturer’s 
protocol. Relative miRNA expression levels were calculated using 18S RNA as reference. 
GDF15 mRNA expression was measured by real-time PCR using the TaqMan® Gene 
Expression assay (Cat # Hs00171132_m1). 
1.3.9. Transient transfection of SW-620 cells with pCEP4-Flag-VDR plasmid 
 We created an expression vector to over express the full length VDR gene in SW-620 
cells. The VDR cDNA was cloned into the pCEP4 vector (Figure 8) to express VDR as a flag-
tagged protein. Full length VDR gene was obtained by polymerase chain reaction using 
expressed-sequence tag clone as a template. Transient transfection was performed in SW-620 
cells with this plasmid using Lipofectamine 
TM
 PLUS reagent (Invitrogen) following 
manufacturer’s protocol. 0.5 μg/ml of plasmid was used to form complexes with transfection 
reagent. pCEP4-Flag-VDR transfected (24h) SW-620 cells were treated with 100 nM calcitriol 
for 24 hours, miR-627 expression was analyzed by real-time PCR. 
 
                                          
                                     
 
 
 
 
 
                           Figure 8.  pCEP4 plasmid (Invitrogen Catalog # V044-50). 
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1.3.10. Transient transfection of HCT-116 cells with miR-627 and miR-NC mimics 
Synthetic miRNA mimics (Pre-miR™ miRNA Precursors) for miRNA-627 (Catalog # 
AM17100) and miR-NC (Catalog # AM17110) were purchased from Ambion. Ambion® Pre-
miR™ miRNA Precursor Molecules are small, chemically modified, double-stranded RNA 
molecules designed to mimic endogenous mature miRNAs. These miRNA mimics were 
transfected into HCT-116 cells using X-tremeGENE siRNA transfection reagent (Roche, 
Indianapolis, IN) following manufacturer’s protocol. 100 nM negative control miRNA or miR-
627 mimic was used for transfection into HCT-116 cells and cell growth was determined at 
various time points using the WST-1 assay. 
1.3.11. Transient transfection of HCT-116 cells with miR-627 or miR-NC plasmids 
We created an expression vector to over express miR-627 or miRNC in HCT-116 colon 
cancer cells. The vector used for this study was a special type of vector from Invitrogen (The 
BLOCK-iT™ Pol II miR RNAi expression vector, Figure 9). Double strand oligoes containing 
pre-miR-627 / miR-NC were cloned into pcDNA6.2-GW/EmGFP-miR plasmid (Invitrogen) by 
directional cloning. This plasmid has a promoter region called PCMV which causes over 
expression of any gene placed adjacent to it. A Green Fluorescence Protein gene (GFP) is placed 
just before the miRNA region so that the over expression of the miRNA could be determined by 
the over expression of the GFP, marked by green fluorescence. Transient transfection was done 
in HCT-116 cells with these plasmids using Lipofectamine 
TM
 PLUS reagent (Invitrogen). 0.5 
μg/ml of plasmid was used to form complexes with transfection reagent. After transfecting the 
HCT-116 cells with miR-627 and miR-NC plasmids, the fluorescence of the cells was observed 
for two days. The increase in the fluorescence showed that the gene inserted in the BLOCK-iT™ 
Pol II miR RNAi expression vector was being overexpressed. To confirm the overexpression of 
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miR-627 in HCT-116 cells, protein was isolated from cells 2 days after transfection and western 
blot was performed to detect JMJD1A. 
 
   
    
 
 
 
 
 
 
Figure 9. The BLOCK-iT™ Pol II miR RNAi expression vector,  
           pcDNA 6.2-GW/EmGFP-miR. (Invitrogen, Catalog # K4936-00).  
 
1.3.12. Transient transfection of HCT-116 cells with negative control or JMJD1A specific 
siRNAs 
 The Silencer® Select siRNAs for JMJD1A (Catalog # 4392420) and negative control 
(Catalog # AM4611) were purchased from Ambion. The Silencer® Select siRNAs are more 
potent than currently available siRNAs with fewer off-target effects. These siRNAs were 
transfected into HCT-116 cells using X-tremeGENE siRNA transfection reagent (Roche, 
Indianspolis, IN) following manufacturer’s protocol. 100 nM negative control or JMJD1A 
specific siRNA was used for transfection into HCT-116 cells and JMJD1A knockdown was 
confirmed by western-blot. Effect of JMJD1A knockdown on cell growth was determined by 
WST-1 assay.  
miR-627 or miR-NC ds oligoes 
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1.3.13. Transient transfection of HCT-116 cells with pCEP4-Flag-JMJD1A plasmid 
 We created an expression vector to over express the full length JMJD1A protein in HCT-
116 cells. The JMJD1A cDNA was cloned into the pCEP4-Flag vector (Figure 7) to express 
JMJD1A as a flag-tagged protein. Full length JMJD1A gene was obtained by polymerase chain 
reaction (PCR) using expressed-sequence tag clone as a template. Transient transfection was 
done in HCT-116 cells with this plasmid using Lipofectamine 
TM
 PLUS reagent (Invitrogen)  
by following manufacturer’s protocol. JMJD1A overexpression was confirmed by western blot 
using anti-Flag antibody.  
1.3.14. Transient transfection of HCT-116 cells with miR-627 and miR-NC inhibitors  
MiRCURY LNA™ microRNA Inhibitors for miR-627 (Catalog # 410399-00) and miR-
NC (Catalog # 199004-00) were purchased from Exiqon.  miRCURY LNA™ microRNA 
inhibitors are ideal for use as specific suppressors of microRNA activity. These miRNA 
inhibitors were transfected into HCT-116 cells using X-tremeGENE siRNA transfection reagent 
(Roche, Indianapolis, IN) following the manufacturer’s protocol. 100 nM LNA-modified 
miRNA inhibitor specific to miR-627 or the negative control inhibitor was used for transfection, 
and cells were treated with 500 nM calcitriol for 48 hours. Total RNA and protein was isolated to 
analyze the miR-627 and JMJD1A expression by RT-PCR and Western blot respectively. 
1.3.15. Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (ChIP) assay was performed using the ChIP assay kit 
from Millipore. Formaldehyde was added directly to the medium containing colon cancer cells 
after desired vitamin D treatment, to crosslink histones to DNA. After incubating cells with 
formaldehyde for 10 minutes at 37
0
C and 5% CO2, media was removed as much as possible. 
Cells were washed twice using ice cold PBS containing protease inhibitors. Cells were scrapped 
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into a conical tube and centrifuged at 2000 rpm for 4 minutes at 4
0
C. Cell pellet was resuspended 
in 200μl of SDS lysis buffer with protease inhibitors and incubated for 10 minutes on ice. We 
used 200μl of SDS lysis buffer per 1 X 106 cells. Cell lysate was sonicated on ice to shear DNA 
into fragments of 200 and 1000 base pairs length (Branson Digital Sonifier, 30 % power, 10 
seconds pulse 3X, 1 minute interval between each pulse). After sonication, the samples were 
centrifuged for 10 minutes at 13,000 rpm and 4
0
C, the cell supernatant was then diluted 10 times 
in ChIP Dilution Buffer, and protease inhibitor cocktail was added as indicated above. 1% 
(20μL) of diluted supernatant was stored at -200C, and was considered as INPUT, and loading 
control. To reduce nonspecific background, 80μl of Salmon Sperm DNA/Protein A Agarose-
50% Slurry was added to 2ml diluted cell supernatant and incubated for 1 hour at 4
0
C with 
agitation. Brief centrifugation (1000 rpm, 1 min at 4
0
C) was performed to pellet the agarose and 
the supernatant fraction was collected. Immunoprecipitations were performed by incubating the 
supernatant fractions with anti- H3K9Me2, H3K4Me3 (Cell Signaling Technology, Danvers, 
MA, 1:200 dilution) and H3K27Me2/Me3 (Active Motif, Carlsbad, CA, 1:200 dilution) or 
control IgG antibodies for overnight at 4ºC with rotation. 60μl of Salmon Sperm DNA/Protein A 
Agarose Slurry was added to the immunoprecipitated complex and incubated for one hour at 4ºC 
with rotation to collect the antibody/histone complex. Protein A agarose /antibody/histone 
complexes were collected by brief centrifugation, these complexes were washed for 3 min on a 
rotating platform with 1 ml of each of the following buffers: 
1.  Low Salt Immune Complex Wash Buffer, (1X)  
2. High Salt Immune Complex Wash Buffer, (1X)  
3. LiCl Immune Complex Wash Buffer, (1X)  
4. 1X Tris-EDTA Buffer, (2X) 
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After each wash, the complexes were centrifuged at 1000 rpm for 1 min at 4
0
C.  Histone 
complexes were eluted from the antibody by incubating with 250μL freshly prepared elution 
buffer (1%SDS, 0.1M NaHCO3) for 15 min at room temperature (RT). After centrifugation at 
13000 rpm for 5 min, the supernatant fractions were collected. The elution process was repeated 
and the eluates were combined (500μL). INPUTS as well as eluates were reverse cross-linked by 
treating with 20μL 5M NaCl at 650C for overnight. Finally, a polymerase chain reaction was 
performed with the primers designed from the sequences of the GDF15 promoter, (5’- 
CTGTCTCTGGCCGAGGCG AG-3’ and 5’-CACTTACCTTCTGGCGTGAGTATCCGG-3’). 
1.3.16. Creation of miR-627 and miR-NC stable expressing HCT-116 cell lines 
 Stable cell lines expressing miR-627 or negative control miRNA were established by 
transfection of HCT-116 cells with BlockiT
TM
 Pol II miR expression vectors: pcDNA6.2-
GW/EmGFP-miR-627 or pcDNA6.2-GW/EmGFP-nega-control. These vectors have a 
blasticidin-resistance and a spectinomycin-resistance gene. XL-1 Blue competent E.Coli bacteria 
from Agilent Technologies were used to amplify the plasmid. The bacterial colonies 
overexpressing miR-627 and miR-NC were selected in spectinomycin-positive agar plates 
(50µg/mL spectinomycin). Both the plasmids were linearized by digesting with ApaL1. 
Linearization of plasmids before the transfection increases the efficiency of stable clone 
generation as well as target gene expression (Grant S. and Gerald M., 2010). Lipofectamin
TM
Plus 
reagent (Invitrogen) was used to transfect miR-627 and miR-NC plasmids into HCT-116 cells. 
The transfected HCT-116 cells were treated with the optimized dose of blasticidin (8µg/mL), 
which selected only cells that had taken up the plasmid containing the resistance gene to 
blasticidin. Due to the presence of a GFP gene placed before the miRNA, the overexpression of 
the miRNA was determined by the green fluorescence of GFP. These GFP colonies were picked 
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and sub-cultured, resulting in HCT-116 stable cell lines overexpressing the miR-627 or miR-NC. 
Stable miR-627 expression was confirmed by checking the JMJD1A expression through western 
blot analysis (Table 4).  
1.3.17. Creation of JMJD1A-3’UTR stable expressing HCT-116 cell lines 
 The 3’UTR (Un Translated Region) cDNA fragment of JMJD1A gene was obtained by 
PCR using EST clone as a template. The JMJD1A-3’UTR cDNA was inserted into pRNAT-
CMV3.2/Puro plasmid (Figure 10, BamH1/Xho1). This vector has a puromycin-resistance and 
an ampicillin-resistance gene. XL-1 Blue competent E.Coli bacteria from Agilent Technologies 
were used to amplify the plasmid. The bacterial colonies overexpressing JMJD1A-3’UTR were 
selected in ampicillin-positive agar plates (100µg/mL Ampicillin). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              Figure 10. pRNAT-CMV3.2/Puro  (GenScript, Catalog # SD1266). 
JMJD1A-3’UTR 
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Plasmid was linearized by digesting with Pvu1. Lipofectamin
TM
Plus reagent (Invitrogen) was 
used to transfect JMJD1A-3’UTR plasmid in to HCT-116 cells. The transfected HCT-116 cells were 
treated with the optimized dose of puromycin (0.4µg/mL), and the cells that took up the plasmid 
continued to grow and form colonies. Expression of the JMJD1A-3’UTR was determined by the 
green fluorescence of GFP, marked by green fluorescence.  These GFP colonies were picked and 
sub-cultured, resulting in HCT-116 stable cell lines overexpressing the JMJD1A-3’UTR. Expression 
of JMJD1A-3’UTR was determined by measuring JMJD1A protein levels in these stable cells before 
and after the calcitriol treatment using western blot analysis (Table 4). 
1.3.18. Site-directed mutagenesis 
                        
 
 
 
 
 
 
 
 
 
 
 
                 Figure 11. QuikChange II site-directed mutagenesis (Agilent Technologies 
                 Cat # 200523). 
1. Mutant Strand Synthesis 
Perform PCR to:  
 denature DNA template  
 anneal mutagenic primers 
containing desired mutation  
 extend and incorporate primers  
with PfuUltra DNA polymerase 
 
 
 
2. Digestion of template by Dpn1 
    Digest parental methylated and  
    hemimethylated DNA with Dpn1 
 
 
 
3. Transformation 
    Transform mutated plasmid 
    into competent cells for nick repair  
 38 
 
The QuikChange site-directed mutagenesis procedure is used to make point mutations, 
delete or insert single or multiple amino acids. As shown in Figure 11, this procedure requires a 
supercoiled double-stranded DNA vector with an insert (gene of interest, JMJD1A-3’UTR) and 
two synthetic oligonucleotide primers containing the desired mutation. Briefly a mutant strand 
was synthesized by performing a polymerase chain reaction (PCR) using a pfuUltra DNA 
polymerase. The original and non-mutated plasmid DNA that remained after the PCR cycles was 
digested with the enzyme DpnI. XL-1 Blue bacteria were used to amplify plasmid DNA 
containing the desired mutation (JMJD1A-3’UTR-MUT).  
1.3.19. Creation of JMJD1A-UTR-MUT stable expressing HCT-116 cell lines 
pRNAT-CMV3.2/Puro plasmid with JMJD1A-3’UTR-MUT insert was used to generate 
these stable cells. This vector has a puromycin-resistance and an ampicillin-resistance gene. XL-
1 Blue bacteria (Agilent Technologies) were used to amplify the plasmid. The bacterial colonies 
overexpressing JMJD1A-3’UTR-MUT were selected in ampicillin-positive agar plates 
(100µg/mL ampicillin). The plasmids were linearized by digesting with Pvu1 prior to the 
transfection. Lipofectamin
TM
Plus reagent (Invitrogen) was used to transfect JMJD1A-3’UTR-
MUT plasmid in to HCT-116 cells. After 24 hours, the transfected HCT-116 cells were treated 
with the optimized dose of puromycin (0.4µg/mL), and the cells that took up the plasmid 
continued to grow and form colonies. Expression of the JMJD1A-3’UTR-MUT was determined 
by the green fluorescence of the GFP. These GFP colonies were picked and sub-cultured to 
create HCT-116 stable cell lines overexpressing the JMJD1A-3’UTR-MUT. Expression of 
JMJD1A-3’UTR-MUT was determined by measuring JMJD1A protein levels in these stable 
cells before and after the calcitriol treatment through western blot analysis (Table 4).  
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Table 4. Stable cell lines summary. 
 
Objective Vector used Target gene tested Section 
Expression of miR-627 
and/or miR-NC 
Expression of JMJD1A-
3’UTR and/or 3’UTR-MUT 
pcDNA6.2-GW/EmGFP 
 
pRNAT-CMV3.2/Puro 
JMJD1A 
 
JMJD1A 
1.3.16. 
 
1.3.17./1.3.19. 
 
1.3.20. Tumor xenografts in nude mice 
 Six to 8-week-old female nude mice (Nu/Nu) were purchased from Charles River 
(Wilmington, MA). The mice were maintained in sterile conditions using the Innovive IVC 
system from Innovive (San Diego, CA), following the protocol approved by the Institutional 
Animal Care and Use Committee of North Dakota State University. Tumor xenografts were 
established by subcutaneous injection of 2 x 10
6
 cancer cells in the flank region of the mice. 
Calcitriol and dimethyl sulfoxide (as control) were administered by intraperitoneal injection. 
Two axes of the tumor (L, longest axis; W, shortest axis) were measured with a digital caliper. 
Tumor volume was calculated as: V = L x W
2
/2. 
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CHAPTER 2: ROLE OF CALCITRIOL INDUCED MIR-627 IN SUPPRESSION OF 
COLON CANCER GROWTH  
 
 The working hypothesis for this part of the study was that, calcitriol induces miR-627 
expression in colon cancer cells. MicroRNA-627 in turn inhibits histone demethylase, JMJD1A, 
resulting in the inhibition of colon cancer growth. The following experiments were performed to 
test our hypothesis. 
2.1. Results and discussion 
2.1.1. Determining the effect of calcitriol on the growth of HCT-116 and HT-29 colon 
cancer cells 
To determine the effects of calcitriol on colon cancer cells, we incubated HCT-116 and HT-
29 cells with various concentrations of calcitriol for 48 hours. At the end of the incubation, WST-1 
reagent (Roche, Indianapolis, IN, USA) was added and placed in the incubator for 30 min. Finally 
absorbance was measured at 440 nm and the percentage of growth inhibition was reported (Figure 
12),  untreated colon cancer cells absorbance was considered as 100 percent cell growth. It was 
observed from the Figure 12, that with increasing concentration of calcitriol, the percentage of cell 
growth significantly decreased both in HCT-116 and HT-29 colon cancer cells. 
2.1.2. Effect of calcitriol on HCT-116 cell cycle distribution 
To find out the mechanism of calcitriol induced growth inhibition, we analyzed the cell cycle 
distribution in calcitriol treated HCT-116 cells using a simple PI staining. Cells were treated with 
calcitriol and stained with PI to analyze the cell cycle distribution on an Accuri C6 flow cytometry. 
As shown in Figure13, calcitriol treatment slightly increased the percentage of cells in the G1 phase 
of cell cycle (but not statistically significant). 
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Figure 12. Calcitriol inhibits the proliferation of colon cancer cells. (A) HCT-116 and (B) HT-29 
cells were treated with various concentrations of calcitriol for 48 hours and in vitro cell proliferation 
was analyzed using WST-1 assay (*p-value < 0.05; ** p-value < 0.01; ***p-value < 0.001). 
 
        
 
 
 
 
 
 
 
Figure 13. Calcitriol had minimal effects on the cell cycle of HCT-116 cells. HCT-116 cells were 
treated with 500 nM calcitriol for 48 hours and cell cycle distribution was analyzed by flow 
cytometry (Control: G1=63.3%, S=14.2%, G2/M=20.7% ; Calcitriol: G1=66.6%, S=12.5%, 
G2/M=19.8%). 
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2.1.3. Flow cytometric analysis of apoptosis using Annexin V in calcitriol treated HCT-116 
cells 
We determined if apoptosis plays a role in calcitriol induced growth suppression in colon 
cancer cells. HCT-116 cells were treated with calcitriol, incubated with Annexin V fluorescein 
conjugate and analyzed for apoptosis using an Accuri C6 flow cytometer. As shown in Figure 14, 
apoptosis induced by calcitriol is very minimal in colon cancer cells.  
        
Figure 14. Calcitriol had minimal effects on apoptosis of HCT-116 cells. HCT-116 cells were treated 
with 500 nM calcitriol for 48 hours, apoptosis was determined by Annexin V staining and flow 
cytometry.  
2.1.4. Western blot analysis of cyclin-dependent kinase (CDK) inhibitors in calcitriol 
treated HCT-116 cells 
Cyclin-dependent kinase inhibitors (CDKIs) bind to and inhibit the activity of CDKs. Two 
major classes of CDK inhibitors have been identified. The p16 family (p15, p16, p18 and p19) binds 
to and inhibits the activities of CDK4 and CDK6. The p21 family (p21, p27, p28 and p57) can bind 
Control Calcitriol 
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to broad range of CDK-cyclin complexes and inhibit their activities. CDKIs are capable of 
suppressing the cancer growth (Bayrak A., Oktay K., 2003). We determined if cyclin-dependent 
kinase inhibitors play a role in calcitriol induced growth suppression in colon cancer cells. HCT-116 
cells were treated with calcitriol for 48 hrs, then protein was isolated and western blot analysis was 
performed using p15, p16, p21, and p27 antibodies. As shown in Figure 15, calcitriol had minimal 
effects on the cyclin-dependent kinase inhibitors. Expressions of p15, p21, and p27 were not 
upregulated by calcitriol, while p16 expression was slightly increased. Previously, it was reported 
that calcitriol induced p21 expression in HCT-116 cells, at a significantly higher dose of 1 µM (Liu 
G., et al 2010).  
               
Figure 15. Effects of calcitriol on the cyclin-dependent kinase inhibitors. HCT-116 cells were treated 
with various doses of calcitriol (100, 200, 500 nM) for 48 hrs and the expression of cell cycle 
regulatory proteins (p15, p16, p21 and p27) was analyzed by western blots. 
2.1.5. Effect of calcitriol on HCT-116 cell cycle progression 
2.1.5.1. Cell doubling time 
To determine if calcitriol caused a general slowdown of the cell cycle, we compared the cell 
doubling time in control and calcitriol treated HCT-116 cells. Control and calcitriol treated cells 
were collected at various time points. Cell number data was used to calculate the cell doubling time 
using an online doubling time calculator (http://www.doubling-time.com/compute.php, Table 5). As 
shown in Figures 16A and B, calcitriol increased the cell doubling time by about 3 hours. 
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Figure 16. Calcitriol increases cell doubling time in colon cancer cells. (A) HCT-116 cells were 
continuously treated with 500 nM calcitriol. Control and calcitriol treated cells were collected at 0h, 
24h, 48h, and 72h. Cell number was determined using hemacytometer and counting under a 
microscope. (B) Cell number data was used to calculate the cell doubling time (Control: 16.5h; 
Calcitriol: 19.47h; * p-value < 0.05). 
   
       Table 5. Various parameters of cell doubling time in calcitriol treated HCT-116 cells. 
 
Parameter Control Calcitriol 500nM 
Doubling Time in hours 16.5 19.47 
Growth Rate 0.042 0.0356 
Equation Amount = 1.2108*e
0.042*time
 Amount = 1.2554*e
0.0356*time
 
Cell Concentration at T= 0 hrs 1.2108 (Folds) 1.2554 (Folds) 
 
2.1.5.2. Cell cycle progression by BrdU pulse chase experiment 
To determine if calcitriol caused a general slowdown of the cell cycle, we also measured cell 
cycle progression by a pulse chase experiment using flow cytometric analaysis. HCT-116 cells were 
treated with calcitriol for 72 hours. BrdU was directly added to the cell culture media (control and 
* 
A. B. 
Hours 
Ctr     Calcitriol 
p < 0.01 
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calcitriol treated) to a final concentration of 10µM. These cells were incubated for 30 minutes at 
37
0
C and 5%CO2. After the 30 min short pulse, cells were washed with media to remove excess 
BrdU and incubated further in normal growth media. At various time points post BrdU pulse cells 
were harvested, washed, fixed in ice-cold ethanol and labeled with anti-BrdU (FITC conjugated) 
followed by propidium iodide (PI), as discussed in materials and methods section. As shown in 
Figures 17A and 17B, HCT-116 cells treated with calcitriol showed a general slowdown of the cell 
cycle. Compared to control, calcitriol treated samples showed more BrdU labeled cells to lag behind 
at all-time points.   
Figure 17A. Calcitriol delayed cell cycle 
progression in HCT-116 cells. HCT-116 cells  
were treated with 500 nM calcitriol for 72 hours. 
Control and calcitriol treated cells were labeled 
with BrdU. Post labeling, cells were stained with 
FITC conjugated anti-BrdU antibody and PI,  
analyzed by flow cytometric analysis.  
(* p < 0.05, **p < 0.01, *** P < 0.001). 
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    Figure 17B. Flow cytometric analysis of control and calcitriol treated HCT-116 cells labeled with anti-BrdU and PI.
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2.1.6. Effect of calcitriol on differential expression of miRNAs in colon cancer cells 
In order to reveal the possible mechanism of how calcitriol inhibits cancer cell growth, we 
investigated the effects of calcitriol on the expression of the microRNAs in HT-29 colon cancer 
cells. We used the mirVana miRNA Bioarray kit from Ambion, to compare the microRNA 
expression profiles in HT-29 cells before and after calcitriol (100nM, 24 hours) treatment. Among 
the 471 human miRNAs examined, miR-627 was the only microRNA whose expression level was 
significantly increased by calcitriol treatment. List of dysregualted miRNAs are shown in Tables 6 
and 7. It was observed that the miR-627 expression was up-regulated most significantly in calcitriol 
treated HT-29 cells as compared to control HT-29 cells. Therefore, miR-627 was selected to 
investigate its potential role in colon cancer treatment. MiR-627 is one of the miRNAs identified in a 
recent genome-wide miRNA expression study in colon cancer cells (Cummins J.M., et al., 2006). 
  Table 6. List of miRNA that are increased by calcitriol treatment in HT-29 cells. 
 
Name of miRNA Average fluorescence ratio 
of calcitriol/control 
Standard deviation 
let-7g 1.279 0.073 
miR-28 1.342 0.091 
miR-346 1.345 0.256 
miR-627 6.458 1.239 
 
          NOTE: The fold of changes in miRNA levels in calcitriol treated cells compared to  
          control cells is indicated by the ratio of fluorescence of the two samples. For example,  
          a ratio of 6.458 indicates 545.8% increase of the miRNA in the calcitriol treated cells. 
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         Table 7. List of miRNA that are decreased by calcitriol treatment in HT-29 cells. 
 
NOTE: The fold of changes in miRNA levels in calcitriol treated cells compared to  
control cells is indicated by the ratio of fluorescence of the two samples. For example,  
   a ratio of 0.365 indicates 63.5% decrease of the miRNA in the calcitriol treated cells. 
Name of miRNA Average fluorescence ratio of 
calcitriol/control 
Standard deviation 
miR-125a 0.486 0.021 
miR-133b 0.585 0.1 
miR-139 0.837 0.1 
miR-154 0.366 0.061 
miR-196a 0.669 0.021 
miR-26a 0.715 0.057 
miR-296 0.686 0.071 
miR-30b 0.47 0.071 
miR-33 0.709 0.044 
miR-491 0.471 0.093 
miR-499 0.553 0.042 
miR-517a 0.648 0.017 
miR-518a 0.37 0.06 
miR-532 0.667 0.148 
miR-549 0.526 0.058 
miR-553 0.834 0.016 
miR-557 0.365 0.004 
miR-571 0.62 0.147 
miR-579 0.627 0.139 
miR-591 0.57 0.055 
miR-595 0.613 0.079 
miR-597 0555 0.062 
miR-600 0.57 0.155 
miR-608 0.456 0.004 
miR-637 0.533 0.015 
miR-646 0.73 0.158 
miR-662 0.8 0.234 
miR-9-AS 0.452 0.008 
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2.1.7. Confirmation of miRNA expression by real-time PCR 
In order to confirm the results from the microarray-based miRNA expression profiling and to 
quantify the relative levels of miR-627, we performed Real-Time Polymerase Chain Reaction (RT-
PCR) in control and calcitriol treated HCT-116 and HT-29 colon cancer cell lines. As evident from 
Figure 18, miR-627 levels were significantly upregulated in calcitriol treated HCT-116 and HT-29 
colon cancer cell lines. These results indicate that miR-627 may be a major epigenetic regulator in 
the calcitriol induced growth inhibition in colon cancer cells. 
 
 
 
 
 
Figure 18. Calcitriol induces miRNA-627 expression in colon cancer cells. HCT-116 and HT-29 
cells were treated with 100 nM calcitriol for 24 hours and total RNA was isolated from the cells and 
analyzed by RT-PCR (* p < 0.05; *** p < 0.001). 
2.1.8. Vitamin D receptor and miR-627 expression in SW620 cells 
In order to determine the involvement of vitamin D receptor (VDR) for the activation of 
miR-627 expression, we observed the effects of calcitriol in SW620 cells. SW620 is a colon cancer 
cell line which expresses extremely low level of vitamin D receptor VDR, not detectable by 
Northern Blot (Palmer H.G., et al., 2001). The VDR cDNA was cloned into the pCEP4-Flag vector 
to express VDR as a Flag-tagged protein. Real-time PCR was performed in control and calcitriol 
*** 
 * 
 50 
 
0
1
2
3
4
Control Calcitriol 100nM Tag2A-ControlVDR-Calcitriol 100nM
R
el
a
ti
v
e 
m
iR
-6
2
7
 L
ev
el
s 
SW-620 cells 
treated SW620 cells to measure the miR-627 expression levels. As shown in the Figure 19, calcitriol 
induced miR-627 expression at a level relatively lower than that in HT-29 or HCT-116 cells 
(comparing with Figure 18). However, after transfection of SW620 cells with a plasmid to 
overexpress full length VDR, calcitriol induced miR-627 expression to a level similar to that in HT-
29 or HCT-116 cells (Figure 19). Therefore, the results indicated that both genomic (VDR-
dependent) and non-genomic mechanisms may be required for calcitriol to induce miR-627 
expression in colon cancer cells.   
 
 
 
 
 
 
 
 
Figure 19. Calcitriol induces miR-627 expression in SW-620 cells, after VDR overexpression. 
Untransfected or pCEP-Flag-VDR transfected SW-620 cells were treated with 100 nM calcitriol for 
24 hrs, total RNA was isolated and analyzed by RT-PCR (* p < 0.05). 
2.1.9. Effect of miRNA-627 on colon cancer cell proliferation 
To determine the effects of miR-627 on colon cancer cell proliferation, we transfected 
synthetic miRNA-627 and miR-negative control (miR-NC) mimics into HCT-116 cells using X-
tremeGENE siRNA transfection reagent following manufacturer’s protocol. At the end of 24, 48, 
and 72 hours after transfection WST-1 reagent was added and placed in the incubator for 30 min. 
* 
* 
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Finally absorbance was measured at a wavelength of 440 nm and growth curves were reported. As 
shown in Figure 20, synthetic miR-627 significantly inhibited colon cancer cell growth while the 
negative control miRNA had no effect. Thus, miR-627 may mediate the anti-proliferative activity of 
calcitriol.  
      
 
 
 
 
 
 
 
Figure 20. MiR-627 overexpression significantly inhibited the growth of HCT-116 cells. HCT-116 
cells were transfected with 100 nM negative control miRNA or miR-627 mimic. Cell growth was 
determined at various time points after transfection by WST-1 Assay  (* p < 0.05; *** p < 0.001). 
 
2.1.10. JMJD1A is the potential target of miR-627 
 Once we confirmed the inhibitory effect of miR-627 on the growth of HCT-116 colon  
cancer cells, we searched online databases (www.microrna.org and miRBase) to found out the 
gene which is  potentially targeted by miR-627 and we found that miR-627 may repress the 
expression of the histone demethylase, JMJD1A (Jumonji Domain containing 1A) by binding to 
its 3’ untranslated region (UTR). Figure 21, shows the partial complementarity between the miR-
627 and JMJD1A-3’UTR. JMJD1A is an iron- and 2-oxoglutarate-dependent dioxygenase which 
*** 
*** 
* 
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specifically catalyzes  the demethylation of mono and dimethylated Lys-9 of histone H3, with a 
preference for  dimethylated residue, thereby playing a crucial role in histone code (Yamane K., 
et al., 2006). JMJD1A has recently been shown to promote colon cancer growth by mediating the 
effects of HIF-1. (Krieg A.J., et al., 2010) The growth-promoting activity of JMJD1A makes it 
an interesting target for miR-627.      
 
 
          Figure 21. Predicted duplex formation between human JMJD1A-3’-UTR and miR-627. 
 
To confirm that the JMJD1A-3’UTR is the target of miR-627, a cDNA fragment containing 
the 3’UTR sequence of JMJD1A was inserted downstream of the GFP gene in the pEGFP-C1 
plasmid and the plasmid was transfected into HCT-116 cells together with pcDNA6.2-GW-miR-627 
(to overexpress miR-627), GFP expression (western blot analysis) was significantly reduced 
comparing with cells transfected with pEGFP-JMJD1A-3’UTR and pcDNA6.2-GW-negative-
control plasmids (Figure 23A). The action of miR-627 was dependent on the miRNA binding site 
within the JMJD1A 3’UTR, because GFP expression was not reduced by miR-627 when the 
JMJD1A-3’UTR binding site was mutated (Figure 23B) by the QuickChange II site-directed 
mutagenesis procedure. Mutation was performed within the miR-627 recognition site (AUUC to 
UGAG mutation, Figure 22) of JMJD1A 3’UTR. For co-transfection of pEGFP-JMJD1A-3’UTR 
and miRNA expression vectors, EmGFP was removed from pcDNA6.2-GW/EmGFP-miR-627 using 
Dra I digestion to create pcDNA6.2-GW-miR-627, prior to the transfection.          
 
 
         3' agGAGAAAAGAAUCUCUGAGUg 5'     hsa-miR-627 
                  |  |     |           |  |  |     |  |  |  |  : |  |  |  
    5' ucCUGUGGACUUUGAGAUUCAu 3' JMJD1A UTR 
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         3' agGAGAAAAGAAUCUCUGAGUg 5'     hsa-miR-627 
                  |  |     |           |  |  |     |  |  |             |  
    5' ucCUGUGGACUUUGAGUGAGAu 3' JMJD1A UTR-MUT 
                            
 
 
  Figure 22. Compromised complimentarity between human miR-627 and  
     JMJD1A-3'UTR-MUT, after Site-Directed Mutagenesis. 
               
 
 
 
 
         GFP/Tubulin     1      0.38              1   0.9 
Figure 23. JMJD1A is the potential target of miR-627. HCT-116 cells were transfected with GFP-
JMJD1A- 3’UTR (A) or GFP-JMJD1A-3’UTR-MUT (B) plasmid together with plasmids  
expressing miR-627 or a negative control miRNA. Western blotting was performed with anti-GFP 
and anti-tubulin antibodies.  
2.1.11. Transient over expression of miR-627 in HCT-116 colon cancer cells 
 To further confirm that miR-627 targets JMJD1A, we used the BLOCK-iT™ Pol II miR 
RNAi expression vector to over express miR-627 in HCT-116 colon cancer cells. It has a PCMV 
promoter region which causes over expression of any gene placed adjacent to it. Green Fluorescence 
Protein gene (GFP) was placed just before the miRNA region so that the over expression of the 
miRNA could be determined by the over expression of the GFP, marked by green fluorescence. 
HCT-116 cells were transfected with pcDNA6.2-GW/EmGFP-miR-NC or miR-627 plasmids using 
Lipofectamine reagent and fluorescence was monitored for 48 hours. As shown in Figure 24, the 
A. B. 
GFP-JMJD1A- 3’UTR-MUT  
         miR-NC   miR-627  
GFP-JMJD1A- 3’UTR 
   miR-NC  miR-627  
GFP 
β-Tubulin 
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increase in fluorescence confirmed that the miR-627 or miR-NC gene inserted in the expression 
vector was being overexpressed. To check the effect of miR-627 overexpression in HCT-116 cells, 
western blot analysis was performed. It was found that histone demethylase, JMJD1A levels were 
significantly downregulated due to the overexpression of miR-627 (Figure 25), and this could make 
the colon cancer cells susceptible to the calcitriol induced growth inhibition.       
            Bright Field                                    Green Fluorescence 
                   
  After 24 hours of pcDNA6.2-GW/EmGFP-miR-627 Transfection 
       Bright Field                     Green Fluorescence 
                  
   After 48 hours of pcDNA6.2-GW/EmGFP-miR-627 Transfection 
Figure 24. Fluorescence microscopy images showing the gradual increase in GFP expression in     
HCT-116 cells from day 1 to day 2 (10X magnification). 
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  JMJD1A/Tubulin           1               0.19 
Figure 25. MiR-627 overexpression significantly decreased JMJD1A expression. HCT-116 cells 
were transfeted with pcDNA6.2-GW/EmGFP-miR-NC or miR-627 plasmids. 48 hours after 
transfection, cell lysates were analyzed by western blots using anti-JMJD1A and anti-tubulin 
antibodies.   
2.1.12. Calcitriol inhibits JMJD1A expression in HT-29 and HCT-116 cells 
If miR-627 targets JMJD1A, then calcitriol should decrease JMJD1A because it induces 
miR-627. The expression level of the histone demethylase gene, JMJD1A was compared in the 
control and calcitriol treated HT-29 and HCT-116 colon cancer cell lines. It was hypothesized that 
since the miR-627 levels were elevated in calcitriol treated colon cancer cells, so the expression of 
the respective histone demethylase gene should be repressed in these cells and the reverse should be 
true for the control colon cancer cells. To test this hypothesis, western blot was performed with 
control and calcitriol treated HT-29 and HCT-116 cells. Indeed we observed a gradual decrease in 
JMJD1A expression after calcitriol treatment (Figure 26) in HCT-116 and HT-29 cells as compared 
to the level of JMJD1a in untreated colon cancer cells. 
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Figure 26. Calcitriol decreases histone demethylase,  JMJD1A expression in colon cancer cells.   
HCT-116 and HT-29 cells were treated with calcitriol (100, 200, and 500 nM) for 48 hours, and  
cell lysates were analyzed by western blot using anti-JMJD1A and anti-tubulin antibodies. 
2.1.13. Effect of JMJD1A expression on HCT-116 cell proliferation 
2.1.13.1. JMJD1A knockdown 
 To further determine the role of miR-627 dependent suppression of JMJD1A in colon cancer 
growth, we specifically knocked down JMJD1A using small interfering RNA (siRNA).  The 
Silencer® Select siRNAs for JMJD1A and negative control were transfected into HCT-116 cells. 
Forty eight hours after transfection, proteins were isolated and JMJD1A knockdown was confirmed 
by western-blot analysis (Figure 27B).  
 
 
JMJD1A 
β-Tubulin 
                     HCT-116 
       Ctr         100           200           500     Calcitriol in nM  
JMJD1A 
β-Tubulin 
                     HT-29 
       Ctr         100           200         500     Calcitriol in nM  
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                 1        0.36   JMJD1A/Tubulin                           
    
Figure 27.  JMJD1A knockdown significantly decreased the proliferation of colon cancer cells. 
HCT-116 cells were transfected with 100 nM negative control or JMJD1A specific siRNAs. (A) Cell 
growth was determined at 0h, 24h, 48h, and 72h after transfection by WST-1 assay. (B) Knockdown 
of JMJD1A was confirmed by western blot (** p < 0.01; *** p < 0.001).  
 
To determine the effect of JMJD1A knockdown on colon cancer growth, we transfected siR-
NC or siR-JMJD1A into HCT-116 cells. At various time points after transfection, WST-1 reagent 
was added to the media and placed in the incubator for 30 min. Finally absorbance was measured at 
a wavelength of 440 nm. As shown in Figure 27A, knockdown of JMJD1A significantly inhibited 
the proliferation of HCT-116 cells.                       
2.1.13.2. JMJD1A overexpression 
We created an expression vector to overexpress the full length JMJD1A gene in HCT-
116 cells. The JMJD1A cDNA was cloned into the pCEP4-Flag vector to express JMJD1A as a 
Flag-tagged protein. Transient transfection was done in HCT-116 to overexpress JMJD1A, two 
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days after transfection, proteins were isolated and JMJD1A expression was confirmed by 
western blot analysis. (Figure 28B) 
 
       
Figure 28. JMJD1A overexpression abolished the suppressive effect of miR-627 on cell 
proliferation. HCT-116 cells were transfected with empty vector or pCEP4-Flag-JMJD1A. 24 hours 
after plasmid transfection, cells were transfected with 100 nM negative control miRNA or miR-627 
mimic. (A) Cell growth was determined 48 hours after miRNA transfection by WST-1 assay. (B) 
JMJD1A overexpression was confirmed by western blot using anti-Flag and anti-tubulin antibodies 
(*** p < 0.001). 
To determine the effect of JMJD1A overexpression on colon cancer growth, HCT-116 
cells were transfected with pCEP4-Flag-JMJD1A to overexpress Flag-tagged JMJD1A. After 24 
hours of transfection, cells were transfected with negative control miRNA or miR-627 mimic. 
Cell growth was determined after 48 hours of miRNA transfection by WST-1 assay. As shown in 
the Figure 28A, JMDJ1A overexpression stimulated the cell proliferation in HCT-116 cells. 
More importantly, JMJD1A overexpression significantly abolished the suppressive effect of 
miR-627 on cell proliferation. 
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2.1.14. Calcitriol induced miR-627 mediates the growth inhibitory activity of calcitriol in 
colon cancer cells 
 To further test the hypothesis of miR-627 may mediate the anti-proliferative activity of 
calcitriol, we stably overexpressed a cDNA fragment containing a miR-627 target sequence (a part 
of JMJD1A-3’UTR sequence) in HCT-116 cells. The overexpressed mRNA containing the miR-627 
target sequence (placed adjacent to a strong CMV promoter) served as a “sponge” to sequester and 
neutralize the activity of miR-627. We used this miRNA sponge strategy to create HCT-116 stable 
cell lines (please refer to sections 1.3.17 and 1.3.19) for in vitro and long term in vivo growth studies 
(discussed in the next chapter). 
 
 
     
 
 
 
 
 
 
      Figure 29. Mir-627 mediates the growth inhibitory activity of calcitriol in colon cancer  
      cells. HCT-116 cells stably expressing the JMJD1A 3’UTR sponge (to block miR-627)  
      or the JMJD1A 3’UTR sponge with miR-627 binding site mutation (ATTC to TGAG)  
      were treated with various doses of calcitriol for 48 hours and in vitro cell growth was  
      analyzed using WST-1 assay (** p-value <0.01). 
** 
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                        Calcitriol (nM) 
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When miR-627 was blocked (Figure 29; white bars ), calcitriol failed to suppress the growth 
of HCT-116 cells, indicating that induction of miR-627 is critical to the action of calcitriol. In 
contrast, when the miR-627 binding site was mutated (Figure 29; black bars) calcitriol was still able 
to suppress cancer cell proliferation. 
2.1.15. Calcitriol induced miR-627 mediates the JMJD1A expression in HCT-116 cells 
To further establish the link between calcitriol, miR-627, and JMJD1A expression, we 
blocked the activity of miR-627, by transient transfection of a specific LNA (locked nucleic acid)-
modified synthetic inhibitor that recognizes miR-627 (please refer to the section 1.3.14).           
 
 
 
 
 
 
 
 
 
 
Figure 30. Calcitriol induced miR-627 mediates the JMJD1A expression in colon cancer cells. HCT-
116 cells were transfected with 100 nM LNA-modified miRNA inhibitor specific to miR-627 or the 
negative control inhibitor for 24 hours, and then treated with calcitriol. Total RNA and cell lysates 
were analyzed by RT-PCR (100 nM calcitriol, 24 hours) for miR-627 and western blots (500 nM 
calcitriol, 48 hours) with anti-JMJD1A and anti-tubulin antibodies (* p < 0.05).  
JMJD1A 
Tubulin 
     Ctr             Calcitriol             Ctr              Calcitriol        
Negative Control Inhibitor        miR-627 Inhibitor 
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The effect of these inhibitors on calcitriol induced miR-627 and the decreased JMJD1A 
expression were determined by RT-PCR and Western blot analysis respectively. As shown in Figure 
30, miR-627 inhibitor effectively blocked calcitriol-induced miR-627 and the decrease of JMJD1A 
expression. 
2.1.16. Effect of calcitriol on histone methylation on GDF15 promoter 
 Histone demethylase, JMJD1A demethylates both di- or mono-methylated histone H3 lysine 
9, which are commonly associated with repressed gene promoters. By decreasing JMJD1A 
expression, calcitriol induced miR-627 may increase H3K9 methylation on the promoters of 
JMJD1A target genes, such as the GDF15 gene (Krieg A.J., et al., 2010).  We performed chromatin 
immunoprecipitation (ChIP) assay to determine the effects of calcitriol on histone methylation on the 
promoter region of the GDF15 gene. Immunoprecipitations were performed using anti-dimethyl-
histone H3 lysine 9 (H3K9Me2), and control IgG antibodies. ChiP assay follwed by a PCR analysis, 
we measured the H3K9Me2 levels on the promoter region of GDF15 gene in control and calcitriol 
treated HCT-116 colon cancer cells. As shown in Figure 31, calcitriol induced a significant increase 
of H3K9Me2 on the promoter of the GDF15 gene. As a result, GDF15 mRNA expression was 
suppressed by calcitriol.  
Similarly, by decreasing JMJD1A, miR-627 may increase H3K9 methylation on the 
promoter of GDF15. To determine the effects of miR-627 on histone methylation, we performed 
chromatin immunoprecipitation (ChIP) assay on the promoter region of the GDF15 gene. HCT-116 
cells were transfected with a plasmid to overexpress miR-627. MiR-627 overexpressing cells were 
captured by a CherryPicker-specific antibody bound to IgG-coated magnetic beads using 
CherryPicker Cell Capture & Separation System. Overexpression of miR-627 induced a significant 
increase of H3K9Me2 on the promoter of GDF15 (Figure 32).  
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Figure 31. Calcitriol increases histone methylation, H3K9Me2 levels on GDF15 promoter. HCT-116 
cells were treated with 500 nM calcitriol for 48 hours. ChIP assay was performed using primers 
specific for the GDF15 promoter and the indicated antibodies. Total RNA was isolated and analyzed 
for GDF15 expression by RT-PCR (Input-negative control; IgG-background control; ** p < 0.01).                                     
 
 
 
 
Figure 32. MiR-627 overexpression increases histone methylation, H3K9Me2 levels on GDF15 
promoter. HCT-116 cells were transfected with pCherryPicker2-miR-627 plasmid to overexpress 
miR-627. ChIP assay was performed on miR-627 overexpressing cells using primers specific for the 
GDF15 promoter and the indicated antibodies. 
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We also determined the effects of calcitriol on two additional histone methylation markers. 
Calcitriol decreased histone H3K4 methylation (Figure 33A) and increased histone H3K27 
methylation (Figure 33B) on the promoter of GDF15 gene. Since H3K27 methylation is associated 
with repression of gene expression and H3K4 methylation is associated with active transcription 
(Peterson C.L. and Lanoel M.A 2004; Mosammaparast N. and Shi Y. 2010; Niu X. et al., 2012), the 
observed changes in these two markers may also collectively influence the GDF15 expression. 
 
                
    
 
  
 
Figure 33. Chromatin immunoprecipitation assay to detect the histone methylation (H3K4Me3 and 
H3K27Me2/Me3) levels on GDF15 promoter. HCT-116 cells were treated with 500 nM calcitriol for 
48 hours. ChIP assay was performed as described in Materials and Methods using primers specific 
for the GDF15 promoter and the indicated antibodies. 
2.1.17. Effect of calcitriol on HOXA1 and CCND1 expression in HCT-116 cells 
 Recently, it has been shown that JMJD1A promotes cell cycle progression through the G1/S 
transition by activating HOXA1 and CCND1 (encoding cyclin D1) expression (Figure 34, Cho H.S., 
et al., 2012). As shown in the Figure 26, calcitriol treatment significantly decreased the JMJD1A 
expression in HCT-116 cells.  
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Based on these results, we hypothesized that the expression of HOXA1 and CCND1 will be 
downregulated in HCT-116 cells treated with calcitriol. Indeed our Real-time PCR data (Figure 35) 
showed a significant decrease in the expression of JMJD1A target genes, HOXA1 and CCND1 in 
calcitriol treated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. A proposed model of KDM3A (JMJD1A) mediated enhancement of 
HOXA1dependent CCND1 transcriptional activation through demethylation of  
histone H3K9Me2 (Cho H.S., et al., 2012). 
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Figure 35. Calcitriol decreases the expression of HOXA1 and CCND1 in colon cancer cells. HCT-
116 cells were treated with 500 nM calcitriol for 48 hours. Total RNA was isolated and analyzed for 
HOXA1 and CCND1 expression by RT-PCR. (*** p-value < 0.001). 
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CHAPTER 3: CALCITROL INDUCES MIR-627 EXPRESSION IN TUMOR 
XENOGRAFTS; MIR-627 MEDIATES THE ANTI-TUMOR ACTIVITY OF 
CALCITRIOL 
 
 The working hypothesis for this part of the study was that calcitriol induced miR-627 
expression in colon cancer xenografts will inhibit JMJD1A expression and this would in turn 
decrease the growth of the colon cancer xenografts. The following experiments were performed 
to test our hypothesis. 
 Nude mice (Nu/Nu) were maintained in sterile conditions using the Innovive IVC system, 
following the protocol approved by the Institutional Animal Care and Use Committee of North 
Dakota State University.  
3.1. Results and discussion 
3.1.1. Calcitriol induces miR-627 expression in HT-29 tumor xenografts 
To determine if calcitriol induces miR-627 expression in vivo, we established human colon 
cancer xenografts in nude mice by injecting 2x10
6
 HT-29 colon cancer cells subcutaneously into the 
flank regions of nude mice on both sides. The mice developed tumor xenografts within 5 days and 
were treated with calcitriol for 2 days. For control group the same volume of DMSO was injected. It 
has been reported that, the i.p. injection of 0.5 µg calcitriol per mouse is safe to administer without 
inducing any hypercalcemia (Muindi J.R., et al., 2004). Tumor samples (n=3) were collected 24h 
after the second dose and total RNA was isolated from control and calcitriol treated tumor 
xenografts. Relative miR-627 expression was analyzed by RT-PCR using 18S RNA as reference. As 
shown in Figure 36, calcitriol induced miR-627 expression in the tumor xenografts.  
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Figure 36. Calcitriol induces the miR-627 expression in HT-29 colon tumor xenografts. Nude mice 
bearing HT-29 tumor xenografts were treated with calcitriol at intraperitoneal doses of 0.1 μg and 
0.4 μg daily for 2 days. Tumor samples were collected 24 hours after the second dose. Total RNA 
was isolated and miR-627 expression was analyzed by RT-PCR (**p-value < 0.01). 
3.1.2. Calcitriol inhibits JMJD1A expression in HT-29 tumor xenografts 
 It was hypothesized that since the miR-627 levels were elevated in calcitriol treated colon 
tumor xenografts, so the expression of the histone demethylase, JMJD1A should be repressed in 
these tumors and the reverse should be true for the control colon tumors.  
                           
 
 
Figure 37.  Calcitriol decreases histone demethylase, JMJD1A levels in HT-29 colon  
tumor xenografts. Nude mice bearing HT-29 tumor xenografts were treated with  
calcitriol at intraperito-neal doses of 0.1 μg and 0.4 μg daily for 2 days. Tumor samples 
were collected 24 hours after the second dose. Cell lysates were collected and analyzed 
by western blot using anti-JMJD1A and anti-tubulin antibodies.  
** 
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To test this hypothesis, western blot was performed with control and calcitriol treated HT-29 
tumor xenografts. As shown in Figure 37, the expression of JMJD1A was decreased in calcitriol 
treated HT-29 tumor xenografts as compared to control. 
3.1.3. Calcitriol suppressed the growth of HT-29 and HCT-116 colon tumor xenografts 
To determine the effect of calcitriol on in vivo tumor xenografts growth, we established HT-
29 and HCT-116 colon tumor xenografts by injecting 2 million cells SC into the flank regions of 
nude mice (n=5 per each cell line) and waited for 4-6 days for the tumors to develop. Nude mice 
bearing HT-29 and HCT-116 tumor xenografts were treated with calcitriol. The same volume of 
DMSO was administered to the control group. Tumor volumes and body weights were measured at 
indicated time points. 
 
     
 
 
 
Figure 38.  Calcitriol showed no significant toxicity in the nude mice with HT-29 and HCT-116 
tumor xenografts. Nude mice bearing HT-29 (n=9) and HCT-116 (n=7) tumor xenografts were 
treated with calcitriol (i.p. dose of 0.4 µg, 3 injections: 1st week, 2 injections: 2nd and 3rd weeks), 
the same volume of dimethyl sulfoxide (DMSO) was administered to the control groups. Body 
weight was measured as described in Materials and Methods. 
 
    Week 1              Week 2            Week 3   Week 1             Week 2       Week 3 
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Figure  39. Calcitriol slowed down the growth of colon tumor xenografts growth in nude mice.   
Nude mice bearing HT-29 (n=9) and HCT-116 (n=7) tumor xenografts were treated with calcitriol 
(i.p. dose of 0.4 µg, 3 injections: 1st week, 2 injections: 2nd and 3rd week), the same volume of 
DMSO was administered to the control groups. Tumor volume was meaasured as described in 
materials and Methods (*p < 0.05).  
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Calcitriol significantly reduced HT-29 and HCT-116 tumor xenografts growth in the nude 
mice (Figures 39 A & B), without inducing any toxicity (measured by the loss of body weight), as 
shown in Figures 38. We did not observe any other symptoms of toxicity (lethargy, decreased 
feeding). 
3.1.4. MiR-627 is the major epigenetic regulator of calcitriol and mediates the tumor 
xenografts growth inhibition caused by calcitriol 
3.1.4.1. Effect of calcitriol on the growth of HCT116-JMJD1A-3’UTR-SC tumor xenografts 
The JMJD1A-3’UTR cDNA was inserted into pRNAT-CMV3.2/Puro plasmid (BamH I 
and Xho I) to create a pRNAT-CMV3.2/Puro-JMJD1A-3’UTR for stable transfection into HCT-
116 cells. After 48 hours of transfection, cells were treated with the optimized dose of puromycin 
(0.4µg/mL). Cells that take up the plasmid and start expressing the JMJD1A-3’UTR and anti-
puromycin genes in it, continued to grow and formed colonies. Fresh media with an optimized 
puromycin concentration was replaced after every 3 days. Green Fluorescence Protein gene 
(GFP) in the plasmid was used to track the expression of the JMJD1A-3’UTR. These GFP 
colonies were picked and sub-cultured, resulting in HCT-116 stable cell lines overexpressing the 
JMJD1A-3’UTR as well as the GFP (Figure 44).  
 
 
 
 
 
   Figure 40. HCT116-JMJD1A-3’-UTR-SC-8, bright field and FITC (10X) images. 
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We blocked the activity of miR-627 by overexpressing the JMJD1A 3’UTR sponge which 
can sequester miR-627, thus calcitriol was no longer able to decrease JMJD1A (Figure 42A, HCT-
116-JMJD1A-3'UTR-SC-8) . We used HCT116-JMJD1A-3’UTR-SC-8 cells to generate tumor 
xenografts in nude mice. Nude mice with xenografts were separated into control and calcitriol 
groups. Tumor volumes and body weights were measured at indicated time points. There was no 
significant change in the body weight (Figure 41) among the DMSO and calcitriol treated groups. As 
shown in Figure 42B, calcitriol failed to suppress tumor growth in the nude mice when miR-627 was 
blocked by 3’UTR sponge. We did not observe any other symptoms of toxicity (lethargy, decreased 
feeding). 
                                                          
   
 
 
 
 
 
Figure 41. Calcitriol showed no significant toxicity in the nude mice with HCT116-JMJD1A-3'UTR-
SC-8 tumor xenografts. Nude mice bearing HCT116-JMJD1A-3'UTR-SC-8 (n=5) tumor xenografts 
were treated with calcitriol (i.p. dose of 0.4 µg, 3 injections: 1st week, 2 injections: 2nd and 3rd 
weeks), the same volume of dimethyl sulfoxide (DMSO) was administered to the control groups. 
Body weight was measured as described in Materials and Methods. 
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Figure 42. Calcitriol failed to suppress tumor growth in the nude mice with HCT-116-JMJD1A-
3’UTR-SC-8 tumor xenografts. (A) HCT-116 and HCT-116-JMJD1A-3’UTR-SC-8 cells were 
treated with 500 nM calcitriol (Cal) for 48 hours, and cell lysates were analyzed by western blot 
using anti-JMJD1A and anti-tubulin antibodies. (B) Nude mice bearing HCT116-JMJD1A-3'UTR-
SC-8 (n=5) tumor xenografts were treated with calcitriol or DMSO, the same schedule as that in 
Figure 41. Tumor volume was measured as described in Materials and Methods.  
3.1.4.2. Effect of calcitriol on the growth of HCT116-JMJD1A-3’UTR-MUT-SC-4 tumor 
xenografts 
The pRNAT-CMV3.2/Puro-JMJD1A-3’UTR-MUT, containing a mutation within the 
miR-627 recognition site (ATTC to TGAG in the JMJD1A-3’UTR) was created by PCR using 
the QuickChange II site-directed mutagenesis procedure. Similar protocol was followed to create 
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HCT116-JMJD1A-3’UTR-MUT stable cells. Green Fluorescence Protein gene (GFP) in the 
plasmid was used to track the expression of the JMJD1A-3’UTR-MUT. These GFP colonies 
were picked and sub-cultured, resulting in HCT-116 stable cell lines overexpressing the 
JMJD1A-3’UTR-MUT as well as the GFP (Figure 43).   
We used HCT116-JMJD1A-3’UTR-MUT-SC-4 to generate tumor xenografts in nude 
mice. Nude mice with xenografts were separated into control and calcitriol groups, treated with 
DMSO or calcitriol. Tumor volumes and body weights were measured at indicated time points. 
There was no significant change in the body weight (Figure 44A) among the DMSO and 
calcitriol treated groups of nude mice. 
 
 
 
 
 
 
          Figure 43. HCT116-JMJD1A-3’UTR-MUT-SC-4, bright field and FITC (10X) images. 
 
In contrast to the above results from Figure 42, when the miR-627 binding site within the 
JMJD1A-3’UTR sequence was mutated, calcitriol was still able to decrease JMJD1A in HCT-
116-JMJD1A-3'UTR-MUT-SC-4 cells and suppress tumor growth in nude mice (Figure 44B and 
C). 
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Figure 44. Calcitriol suppresses tumor growth in the nude mice with HCT-116-JMJD1A-3’UTR 
-MUT-SC-4 tumor xenografts. (A,C) Nude mice bearing HCT116-JMJD1A-3'UTR-MUT-SC-4 
(n=7) tumor xenografts were treated with calcitriol or DMSO, followed the same schedule as  
that in Figure 41. Body weight and tumor volume were measured as described in Materials and 
Methods. (B) HCT-116-JMJD1A-3’UTR-SC-8 and HCT-116-JMJD1A-3’UTR-MUT-SC-4  
cells were treated with 500 nM calcitriol for 48 hours, and cell lysates were analyzed by  
western blot using anti-JMJD1A and anti-tubulin antibodies (* p < 0.05). 
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3.1.4.3. Effect of miR-627 expression on the growth of colon tumor xenografts 
To determine the effects of miR-627 on in vivo tumor xenograft growth, we established 
HCT-116 cell lines stably expressing negative control miRNA or miR-627. Stable cell lines 
expressing miR-627 or negative control miRNA were established by transfecting HCT-116 cells 
with Block-iTTM Pol II miR expression vectors, pcDNA6.2-GW/EmGFP-miR-627 or 
pcDNA6.2-GW/EmGFP-negative-control. Overexpression of miR-627 was confirmed by 
western blot analysis of decreased JMJD1A expression. (Figure 45B)  
Two million HCT116-miR627-SC-1 or HCT116-miRNC-SC cells were injected S.C. into 
the flank regions of nude mice to develop tumor xenografts. Tumor volumes and body weights 
were measured at indicated time points. As shown in Figures 45C and D, tumors stably 
expressing miR-627 exhibited significantly slower growth compared to tumors expressing 
negative control miRNA. There was no significant change in body weight among the two groups 
of mice (Figure 45A). 
 
 
 
 
 
 
  Figure 45.  MiR-627 overexpression significantly suppresses tumor xenograft growth in nude 
  mice. 
A. 
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Figure 45.  MiR-627 overexpression significantly suppresses tumor xenograft growth in nude mice 
(continued). (A,C) Negative control miRNA or miR-627 expressing stable cell lines were 
transplanted into nude mice to establish tumor xenografts (5 mice per group). Tumor volume and 
body weight were measured as described in Materials and Methods. (B) Cell lysates collected from 
HCT-116 cell lines stably expressing miR-627 or negative control miRNA were analyzed by 
western blot using anti-JMJD1A and anti-tubilin antibodies. (D) Digital image showing the size of 
tumor xenografts stably expressing miR-NC or miR-627 (*** p-value < 0.001). 
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CHAPTER 4: MIR-627 EXPRESION IN HUMAN COLON CANCER SPECIMENS 
 
The working hypothesis for this part of the study was that miR-627 expression will be 
downregulated in human colon cancer specimens compared to normal colon tissues. Decreased 
miR-627 expression would increase the JMJD1A expression in human colon cancer specimens, 
which will stimulate colon cancer growth. The following experiment was performed to measure 
the expression levels of miR-627 in human colon specimens. 
4.1. Results and discussion 
4.1.1. MiR-627 expression in human colon cancer specimens 
  To determine the expression levels of miR-627 in human colon cancers, we analyzed 
RNA samples from human colon adenocarcinoma specimens as well as non-tumor colon mucosa 
tissues (Table 8) by real-time PCR. Total RNAs isolated from human colon adenocarcinomas 
and nontumor colon mucosa tissues were obtained from the Department of Pathology, Roswell 
Park Cancer Institute, and approved by the Institutional Review Board. All RNA samples were 
isolated using Trizol and checked for RIN on Bioanalyzer. The relative miR-627 levels in 
individual samples (Figure 47) were shown compared with one of the normal colon mucosa 
tissue. As shown in Figure 46, miR-627 levels in the tumor specimens were significantly lower 
than those in the normal tissues (Student’s test). Using Pearson's correlation coefficient test, we 
found no association between miR-627 expression levels and tumor stages (r= -0.277, p=0.133) 
or nodal metastases (r=0.181, p=0.236). There were also no correlation between miR-627 
expression and tumor grade of differentiation or tumor sites (left or right colon). It is possible 
that miR-627 expression is decreased during the early stage of carcinogenesis in the colon.  
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Figure 46. Expression of miR-627 decreased in human colon cancer specimens. Total RNA samples 
isolated from 18 human colon adenocarcinomas and 6 nontumor colon mucosa were analyzed for 
miR-627 expression by RT-PCR.  
p < 0.05 
  
 
 
ID 
 
Tumor or Non-tumor 
 
              Grade 
 
Path 
stage 
 
Nodes 
positive 
 
Nodes 
exam 
 
Left or Right colon 
NT1 non tumor colon mucosa     Left Colon 
NT2 non tumor colon mucosa     Left Colon 
NT3 non tumor colon mucosa     Right Colon 
NT4 non tumor colon mucosa     Left Colon 
NT5 non tumor colon mucosa     Colon NOS 
NT6 non tumor colon mucosa     Left Colon 
T1 Adenocarcinoma Moderately differentiated 2  0  25 Left Colon 
T2 Adenocarcinoma Moderately differentiated       2  0 30 Left Colon 
T3 Adenocarcinoma Moderately differentiated        3  10  11 Right Colon 
T4 Adenocarcinoma Poorly differentiated 3 3 18 Transverse Colon 
T5 Adenocarcinoma Moderately differentiated 4 4 20 Right Colon 
T6 Adenocarcinoma Moderately differentiated 4 9 55 Right Colon 
T7 Adenocarcinoma Moderately differentiated 3 1 15 Right Colon 
T8 Adenocarcinoma Moderately differentiated 4 0 14 Left Colon 
T9 Adenocarcinoma Moderately differentiated 1 0 7 Left Colon 
T10 Adenocarcinoma Moderately differentiated 4 0 13 Right Colon 
T11 Adenocarcinoma Moderately differentiated 4 0 19 Right Colon 
T12 Adenocarcinoma Moderately differentiated 3 6 20 Left Colon 
T13 Adenocarcinoma Moderately differentiated 4  2  14 Left Colon 
T14 Adenocarcinoma Poorly differentiated 2 0  11 Left Colon 
T15 Adenocarcinoma Moderately differentiated 4 9  55 Right Colon 
T16 Adenocarcinoma Moderately differentiated 4  9 55 Right Colon 
T17 Adenocarcinoma Moderately differentiated 2 0 33 Transverse Colon 
T18 Adenocarcinoma Moderately differentiated 4 0 22 Left Colon 
Table 8.  List of human colon specimens (NT-Non-tumor; T-Tumor). 
7
9
 
  
 
 
Figure 47.  RT- PCR to measure the relative miR-627 levels in individual human colon cancer specimens compared with 
the ones in normal colon tissue (NT- Non-tumor; T- Tumor).
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CHAPTER 5: SUMMARY AND CONCLUSIONS; CLINICAL IMPLICATIONS AND 
FUTURE DIRECTIONS 
 
5.1. Summary and conclusions 
MicroRNAs have been indicated to play important roles in the regulation of cancer cell 
functions including proliferation (Cheng A.M., et al., 2005), apoptosis (Xu p., et al., 2004), 
differentiation (Karp X. and Ambros V., 2005), invasion and metastasis (Ma L. 2007). 
Microarray based miRNA expression profiling indicated that among the 471 human miRNAs 
examined, miR-627 was the only microRNA whose expression level was significantly increased 
in HT-29 cells by calcitriol treatment. The upregulation of miR-627 by calcitriol was confirmed 
by real-time PCR in HT-29 and HCT-116 cells. Synthetic miR-627 significantly inhibited cancer 
cell growth while the negative control miRNA had no effects, indicating that the miR-627 may 
mediate the anti-proliferative activity of calcitriol.  Using the computational methods available at 
www.microrna.org and miRBase (http://microrna.sanger.ac.uk/), we identified JMJD1A as a 
potential target for miR-627. We selected JMJD1A for further studies because of its known 
involvement in promoting colon cancer growth. JMJD1A has recently been shown to promote 
colon cancer growth by mediating the effects of HIF-1α (Krieg A.J., et al., 2010). The growth-
promoting activity of JMJD1A makes it an interesting target for miR-627.  
Overexpression of miR-627 decreased JMJD1A protein in HCT-116 cells, confirming 
that miR-627 targets JMJD1A. Conversely, transfection of HCT-116 cells with an LNA-
modified synthetic inhibitor anti-miR-627 effectively blocked calcitriol-induced miR-627 and 
the decrease of JMJD1A. Calcitriol, by decreasing JMJD1A induced a significant increase of 
H3K9Me2 on the promoter of GDF15. As a result, GDF15 mRNA expression was suppressed by 
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calcitriol. Other JMJD1A target genes (such as HOXA1, ADM, and EDN1 25) may also be 
downregulated and together contribute to tumor suppression by calcitriol. (Figure 48) 
Calcitriol induced miR-627 expression in vivo in the tumor xenografts while the level of 
JMJD1A was decreased. At the dose of 0.4 μg, calcitriol suppressed tumor growth in the nude 
mice, without inducing significant toxicity (measured by the loss of body weight). When the 
activity of miR-627 was blocked by overexpressing the JMJD1A 3’UTR fragment (which can 
sequester miR-627), calcitriol was no longer able to decrease JMJD1A and also failed to 
suppress tumor growth in the nude mice. In contrast, when the miR-627 binding site within the 
3’UTR sequence was mutated, calcitriol was still able to decrease JMJD1A and suppress tumor 
growth in nude mice. Tumor xenografts stably expressing miR-627 exhibited significantly 
slower growth compared to tumors expressing negative control miRNA, indicating that the miR-
627 suppresses in vivo colon cancer growth. Our data also showed that miR-627 expression was 
lower in human colon cancer specimens than that in normal colon tissues.  
Finally, we have established novel epigenetic mechanisms of calcitriol in suppression 
colon cancer growth. This study has also identified miR-627 and JMJD1A as novel targets for an 
effective treatment of colon cancer.   
 
5.2. Clinical implications and future directions 
Although vitamin D has excellent antitumor activity, its side effect of inducing 
hypercalcemia prevents its use in the clinical treatment of cancer. Our study was able to identify 
the potential novel targets like miR-627 and JMJD1A, downstream of vitamin D, which can be 
used to design new therapy for colon cancer while bypassing the hypercalcemic toxicity. A 
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recent study has demonstrated that the circulating blood vitamin D concentration is inversely 
associated with colorectal cancer risk (Lee J.E., et al., 2011). 
 
 
 
 
 
 
 
 
     Figure 48. A model to describe the role of calcitriol in regulation of miR-627 and JMJD1A  
     levels in colon cancer cells (Activation           ; Inhibition          ). 
Our data showed that miR-627 expression is lower in colon cancer specimens than that in 
the normal colon tissues. Thus, lower blood levels of vitamin D may cause the decrease of miR-
627 expression, which may serve as an important mechanism to promote colon cancer growth. 
So, strategies to over express miR-627 or directly inhibit JMJD1A may prove to be effective 
against colon cancer without eliciting hypercalcemia. 
 The future directions of this project include: (1) Synthesis of novel small molecule 
JMJD1A inhibitors, (2) Systemic delivery of stable and synthetic miR-627, and (3) Use of 
synthetic vitamin D analogues with high anticancer efficacy while being non-toxic.  
1. Synthesis of novel small molecule JMJD1A inhibitors: JMJD demethyases have been 
shown to be overexpressed and plays an importance role in cell proliferation in prostate 
(Wissmann M., et al., 2007), breast (Liu G., et al., 2009), and esophageal cancers (Cloos 
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P.A., et al., 2006). JMJD inhibitors have demonstrated an inhibition of prostate and colon 
cancer cell growth (Hamada S. et al., 2010).  
2. Systemic delivery of stable and synthetic miR-627: In gene therapy, the primary challenge 
is to develop an ideal method to deliver the synthetic miRNA to target cells. An ideal 
delivery method should be non-toxic to cells, protect the RNA from degradation by 
nucleases, and allow efficient miRNA entry into the target cells (Rajagopal N. A. 2013). 
Liposomes are most commonly used to deliver DNA and RNA into the cells, due to their 
long half-lives in systemic circulation as compared to naked oligonucleotides. Liposomes 
also protect the oligonucleotides from degradation and nuclease digestion. It has been 
reported that, neutral liposomes administered systemically were able to deliver the synthetic 
miR-34a and let-7 into the lung tissues of mice and inhibited tumor growth (Wiggins J.F., et 
al., 2010 and Trang P., et al., 2011). Biodegradable polyethanolimine based polymers 
(Pereira D.M., et al., 2013) (alternative to liposomes) carrying miR-34 and miR-145 mimics 
also showed strong inhibition in tumor growth in mouse models of colon cancer (Ibrahim 
A.F., et al., 2011), glioblastoma (Yang Y.p., et al., 2012), and adenocarcinoma of lungs 
(Chiou G.Y., et al., 2012). Atelocollagen (Takeshita F., et al., 2005) based nanoparticles 
carrying mir-34a and LNA-miR-135b were effectively inhibit colon cancer and lymphoma in 
mice, respectively (Tazawa H., et al., 2007 and Matsuyama H., et al., 2011) 
3. Use of synthetic vitamin D analogues with high anticancer efficacy while being non-
toxic:  Vitamin D analogues reduce the proliferation of colon cancer cells in vitro and also 
reduce the tumor xenografts growth in vivo. Several epidemiologic studies show that vitamin 
D deficiency promotes colon cancer growth (Akhter J., et al., 1997 and Evans S.R., et al., 
2000). 
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